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ABSTRACT 
 Primary Myelofibrosis (PMF) is characterized by an increase in megakaryocyte 
(MK) number, augmented bone marrow collagen cross-linking, osteosclerosis and 
splenomegaly. This thesis focuses on elucidating mechanisms behind myelofibrosis and 
osteosclerosis by using the Gata-1low mouse model of PMF, which displays the above 
hallmarks of PMF.  
 Lysyl oxidase (LOX), a facilitator of collagen cross-linking, was reported to 
promote myelofibrosis in the Gata-1low mice. In past studies, Epidermal growth factor 
like 7 (Egfl7) was shown to bind and inhibit LOX. We generated transgenic mice with 
Egfl7 upregulated in MKs on a Gata-1low mouse background (PF4-Egfl7/Gata-1low 
founders # 2 and # 19) to test the hypothesis that Egfl7 inhibits LOX and decreases 
myelofibrosis. We found an increase in MK Egfl7 mRNA expression in transgenic mice 
over Gata-llow controls, but Egfl7 protein was not detected by western blotting in in vitro 
differentiated mature MK lysate and supernatant. At 30 weeks of age, the percentage of 
bone marrow MKs (WT n=4; Gata-1low n=5; #19 n=6; #2 n=2), platelet count (WT n=3; 
Gata-1low n=10; #19 n=11; #2 n=4), spleen weight/body weight (WT n=3; Gata-1low 
	vii 
n=11; #19 n=11; #2 n=4) and bone marrow fibrosis (WT n=5; Gata-1low n=8; #19 n=4; 
#2 n=3) were not statistically different in the experimental groups, with platelet number 
tending to be greater in transgenic compared to Gata-1low mice. More studies are needed 
to measure Egfl7 protein in blood serum and primary MKs, to increase sample size, and 
to examine our hypothesis in mice with greater transgenic expression of Egfl7. 
 Osteosclerosis is an increase in trabecular bone formation in the medullary cavity 
of the femur. Our studies showed an increase in the progression of trabecular bone 
infiltration into the medullary cavity of the Gata-1low female versus Gata-1low male 
mice at ages 10-30 weeks old that was not due to differences in Gata-1 mRNA expression 
levels, osteoclast number per bone surface area (these cells promote bone resorption), or 
MK number (source of growth factors) in the bone marrow. This finding opens 
possibilities for studies that focus on the role of sex hormones and osteoblast 
differentiation in the progression of osteosclerosis in the Gata-1low mice. 
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CHAPTER I. INTRODUCTION 
Overview 
Myeloproliferative Neoplasms (MPNs) are a group of cancers that result from the 
proliferation of progenitor cells within the bone marrow that give rise to erythrocytes, 
granulocytes, platelets, monocytes and mast cells (Vardiman, Thiele et al. 2009). The 
neoplastic myeloid cells in MPN are clonal meaning that the neoplastic cells originate 
from a single progenitor cell (or clone) that gains a proliferative advantage and 
outcompetes other progenitor cells in the bone marrow (Gilliland, Blanchard et al. 1991, 
el-Kassar, Hetet et al. 1997). MPNs are characterized by collagen fiber accumulation in 
the bone marrow (myelofibrosis) and trabecular bone accumulation in the bone marrow 
(osteosclerosis) to varying degrees (Buhr, Busche et al. 2003, Marcinek, Plank et al. 
2008, Barbui, Thiele et al. 2012). Several studies have shown that the progression of 
myelofibrosis and osteosclerosis in myeloproliferative neoplasms is associated with 
poorer outcomes in patients (Buhr, Busche et al. 2003, Thiele and Kvasnicka 2006). 
Patients with myelofibrosis that are classified as high risk according to the Dynamic 
International Prognostic Scoring System (DIPSS) have a median survival of 1.5 years, 
patients with intermediate risk have a median survival of 4 years and patients classified as 
low risk have a median survival of 14.2 years (Passamonti, Cervantes et al. 2010). The 
only curative treatment for myelofibrosis is bone marrow transplantation from a healthy 
donor (termed allogeneic stem cell transplantation), which is reserved for intermediate 
and high-risk patient groups (Barbui, Barosi et al. 2011). The survival rate post-
transplantation for patients with myelofibrosis is 50% (Barbui, Barosi et al. 2011). New 
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therapies targeting the neoplastic cells are currently being developed and tested. Studies 
exploring the mechanism of the evolution of myelofibrosis and osteosclerosis are 
important for better treatment options.   
The goal of this thesis is to provide greater insights into the mechanism of MPNs 
by using the Gata-1low mouse model of myelofibrosis to (1) examine the role of 
Epidermal Growth Factor Like 7 (Egfl7) in myelofibrotic disease and (2) examine the 
progression of osteosclerosis in myelofibrotic disease. 
Bone Marrow Structure and Function  
 The bone marrow is a spongy tissue in the medullary space of the bone that is the 
primary location of non-pathologic adult hematopoiesis (Travlos 2006). Hematopoietic 
stem cells (HSCs) are long-lived cells that reside in the bone marrow and have the ability 
to self-renew or differentiate into multipotent progenitors (MPPs) that eventually give 
rise to fully differentiated blood cells that do not have the ability to self-renew or 
differentiate further. Therefore, HSCs are the key to the regeneration of short-lived 
terminal blood cells. The MPPs self-renew or differentiate into the common myeloid 
progenitor (CMP) or the common lymphoid progenitor (CLP). The CMP differentiates 
into the myeloid lineage, which consists of megakaryocytes, mast cells, monocytes, 
erythrocytes and granulocytes, while the CLP differentiates into B cells, T cells and 
dendritic cells (Summarized in Illustration 1) (Seita and Weissman 2010).  
The bone marrow is anatomically divided into microenvironments that promote 
different stages of HSC differentiation termed the endosteal niche (near the endosteum of 
the bone) and the perivascular niche (near the vasculature in the medullary cavity of the 
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bone) (Seita and Weissman 2010). The endosteum is the inner layer of bone that lines the 
medullary space while the medullary cavity is the central portion of the bone and the area 
where hematopoietic cells and stromal cells are located. Maintenance of these niches is 
important for successful hematopoiesis and blood cell formation.  
In addition to HSCs, the bone marrow also consists of mesenchymal stem cells 
(MSCs), which have the ability to differentiate into adipocytes, osteoblasts and 
chondrocytes (Pittenger, Mackay et al. 1999).  White adipocytes are fat cells that contain 
one large lipid droplet and have the ability to store energy and secrete adipokines to 
regulate energy homeostasis (Sanchez-Gurmaches, Hung et al. 2016). It is known that the 
number of adipocytes in the bone marrow is inversely proportional to the amount of 
active hematopoiesis occurring in the bone marrow and that adipocytes can repress 
hematopoiesis (Naveiras, Nardi et al. 2009). Osteoblasts are cells that secrete bone matrix 
and thus promote the building of bone. They participate in the process of bone 
remodeling by cross talk with osteocytes (mechanosensors within the bone) and 
osteoclasts (cells that resorb bone) so that homeostasis in bone formation and bone 
resorption can be achieved.  Osteoblasts have been found to play a supportive role in 
hematopoiesis by providing a niche for HSCs and several hematopoietic cells including 
megakaryocytes. This means that a lack of proliferative osteoblasts can have a huge 
impact on the maintenance of hematopoiesis (Agas, Marchetti et al. 2015). The other cell 
type that differentiates from MSCs is chondrocytes. These cells are responsible for 
trabecular bone formation within the marrow space because they secrete extracellular 
matrix, become hypertrophic and provide a template on which osteoblasts form bone. 
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Studies on the ability of chondrocytes to regulate hematopoiesis are few, but it is 
understood that a lack of chondrocyte formation negatively impacts hematopoiesis by 
disturbing the bone marrow niche of hematopoietic cells (Sweeney, Roberts et al. 2011).  
 The location of hematopoiesis varies widely throughout development of the fetus 
and maturation into adulthood. Hematopoiesis begins in blood islands of the yolk sac of 
the embryo just after gastrulation. At this point, erythrocytes, platelet producing 
megakaryocytes and macrophages arising from monopotent precursors are present. Later, 
hematopoiesis moves to the aorto-gonadal mesoderm (AGM) followed by the fetal liver, 
thymus, spleen and finally the bone marrow (Chotinantakul and Leeanansaksiri 2012). 
Embryonic sites of hematopoiesis have the ability to become active again in the adult in a 
process termed “extramedullary hematopoiesis”. This leads to hematopoiesis outside of 
the bone marrow in primarily the spleen and liver, which results in splenomegaly 
(enlarged spleen) or hepatomegaly (enlarged liver). The causes of extramedullary 
hematopoiesis vary and include overstimulation of bone marrow cells to proliferate, bone 
marrow injury, inflammation or bone marrow failure (Johns and Christopher 2012).  
Megakaryocyte Structure, Function and Development 
Megakaryocytes are large cells that comprise ~0.05% of the nucleated cells in the bone 
marrow (Nakeff and Maat 1974). The size of the megakaryocyte can be up to ~50µM, 
which is ~10 times the size of a red blood cell and ~3 times the size of a neutrophil, 
resulting in the megakaryocyte being one of the largest and most rare cells in the bone 
marrow (Tomer, Harker et al. 1987). Despite its rarity, the megakaryocyte has been 
extensively studied (Wright 1906, Kaushansky 2008). In 1890, Dr. W.H. Howell stained 
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several tissues from a cat and ascribed the name “megakaryocyte” to the large cells with 
a segmented nucleus that he witnessed in the bone marrow using various staining 
methods and light microscopy (Howell 1890). He came to the conclusion that 
“megakaryocytes” are not in the same lineage as “polykaryoctes” (currently termed 
osteoclasts) on the basis that polykaryocytes are large cells with “multiple nuclei” and 
megakaryocytes are large cells with “budding nuclei” (Howell 1890). Dr. Howell’s 
conclusion paved the way for more studies on the structure and function of 
megakaryocytes.  
The function of megakaryocytes was first described in 1906 when Dr. James 
Homer Wright made the connection that “blood plates” are cytoplasmic remnants of 
megakaryocytes released from cytoplasmic extensions into blood vessels by staining the 
cat bone marrow with his modified version of the Romanofsky polychrome stain 
(currently termed the “Wright Stain”) and visualizing the tissue sections using light 
microscopy (Wright 1906). He came to this conclusion because the “blood plates” in the 
blood (currently termed “platelets”) contain the same granules as the large 
megakaryocytes seen in the cat bone marrow. He noticed that the diameter and 
composition of the cytoplasmic extensions of the megakaryocytes seen entering the blood 
vessels were predictive of the size and composition of the “blood plates” (Wright 1906). 
This novel finding of the origin of blood platelets has been instrumental in the studies of 
diseases that lead to thrombocytopenia (decreased platelet counts) and thrombocythemia 
(increased platelet counts).  
 The cytoplasmic extensions seen by Dr. Wright in 1906 have been further 
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described in the literature and termed “proplatelets”. In 1980, Drs. Radley and Scurfield 
used electron microscopy to describe proplatelets in situ and found that proplatelets 
consist of platelet-sized swellings connected by thin portions of cytoplasm (Radley and 
Scurfield 1980). Microtubules were seen extending along the long axis of the proplatelet, 
and organelles normally identified in peripheral platelets such as endoplasmic reticulum, 
the golgi apparatus, secretory granules, mitochondria, ribosomes and tubules were also 
identified in proplatelets (Radley and Scurfield 1980). In 1990, Tablin et al. cultured 
guinea pig megakaryocytes on rat tail collagen and visualized the fragmentation of 
megakaryocytes and the release of platelets by electron microscopy (Tablin, Castro et al. 
1990). Though megakaryocytes had been documented to form processes in vitro up to 
then, they had not been shown to release platelets. In 1998, Choi et al. used CD34+ 
human stem cells differentiated in vitro into megakaryocytes and then stimulated the 
resulting megakaryocytes to make proplatelets (Choi, Nichol et al. 1995). They found 
that proplatelets were positive for several megakaryocyte and platelet specific proteins 
such as CD42, CD41 and fibrinogen (Choi, Nichol et al. 1995). The proplatelets and 
platelets generated by the megakaryocytes were positive for microtubules, revealed by 
indirect immunofluorescence using an anti-tubulin cocktail of antibodies (Choi, Nichol et 
al. 1995). In addition, secretory granules and platelet-sized swellings were seen by 
electron microscopy and platelets produced by the megakaryocytes were seen to 
aggregate upon stimulation with the platelet aggregation agonists thrombin, fibrinogen 
and adenosine diphosphate (ADP) (Choi, Nichol et al. 1995). These studies were 
important for characterization of proplatelets and the understanding of platelet 
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production, but the limitation remained that platelet production from proplatelets had not 
been visualized in vivo.  In 2008, Junt et al. visualized platelet production in the bone 
marrow of the skull of a mouse expressing the enhanced yellow fluorescent protein 
(eYFP) tag from the CD41 locus in megakaryocytes and platelets (Junt, Schulze et al. 
2007). They were able to visualize proplatelets being formed from megakaryocytes and 
extending into blood vessels (Junt, Schulze et al. 2007). Proplatelets continue to be 
studied as they are the last contact that platelets have with the cell body of 
megakaryocytes and are, therefore, very important for fully functional platelets.  
The mechanism of proplatelet formation has been found to rely on a properly 
formed cytoskeleton within the megakaryocyte. It has been shown that the inhibition of β 
tubulin leads to a lack of fragmentation of megakaryocytes and decreased platelet release 
(Tablin, Castro et al. 1990). β1 tubulin is a lineage specific tubulin that is present only in 
megakaryocytes (Schwer, Lecine et al. 2001). Studies in the β1 tubulin knock-out mice 
have shown that despite a normal megakaryocyte output from in vitro differentiated fetal 
liver cells, the platelet count is very low due to decreased proplatelet production (Schwer, 
Lecine et al. 2001). Actin is another cytoskeletal protein that is important for proplatelet 
production. It has been shown that the inhibition of actin by cytochalasins causes 
decreased proplatelet branching which leads to a decrease in the surface area on the ends 
of proplatelets and a lower production of platelets (Italiano, Lecine et al. 1999, Italiano 
and Shivdasani 2003).   
 Normal proplatelet formation allows megakaryocytes to produce 1x103 platelets 
per cell in humans (Bluteau, Lordier et al. 2009). Megakaryocytes undergo endomitosis 
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and cytoplasmic maturation as they move towards differentiation and platelet formation. 
Endomitosis is the process of mitosis without cytokinesis that leads to a greater than 2n 
amount of DNA in the megakaryocyte (Ravid, Lu et al. 2002). The number of copies of 
DNA is designated as the ploidy of the megakaryocyte. For example, a megakaryocyte 
that has not undergone endomitosis has two copies of DNA and a ploidy of 2n and a 
megakaryocyte that has undergone endomitosis two times has 4 copies of DNA and a 
ploidy of 4n. Megakaryocytes have been found with a ploidy of 2n, 4n, 16n, 32n, 64n and 
132n, which indicates that each megakaryocyte can undergo several rounds of 
endomitosis in a process called polyploidization (Tomer, Harker et al. 1987). Higher 
ploidy megakaryocytes have been theorized to allow for more platelet production because 
of the amount of protein that can be produced from multiple copies of DNA in one cell 
(Bluteau, Lordier et al. 2009).   
 Megakaryocytes that undergo endomitosis have a defect in the proper formation 
of the cleavage furrow, which is responsible for the constriction of the cell membrane 
during late anaphase and subsequent cell division (Machlus and Italiano 2013). The 
cleavage furrow consists of an actomyosin contraction ring, which is dependent on the 
small GTPase RhoA (Machlus and Italiano 2013). Papadantonakis et al. showed that high 
ploidy megakaryocytes (>8n) lack the signs of a cleavage furrow that are present in low 
ploidy megakaryocytes by overexpressing a GFP-tagged DNA marker in the 
megakaryocyte of mice (Papadantonakis, Makitalo et al. 2008).  In 2008, Lordier et al. 
completed a study aimed at visualizing endomitosis in order to gain a better 
understanding of the proteins that are important in cleavage furrow ingression (Lordier, 
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Jalil et al. 2008). They transduced CD34+ derived differentiating megakaryocytes with a 
GFP-tagged Histone 2B DNA marker in order to visualize formation and ingression of 
the cleavage furrow (Lordier, Jalil et al. 2008). Upon fixation and labeling of F-actin and 
myosin IIa, two major components of the cleavage furrow in megakaryocytes, it was 
found that neither protein accumulated in the cleavage furrow during endomitosis to the 
extent that they do during mitosis (Lordier, Jalil et al. 2008). In addition, Rho A was 
found to be the principle factor in regulating the ability of myosin II and F-actin to 
localize to the cleavage furrow (Lordier, Jalil et al. 2008). Further studies in 
megakaryocytes differentiated from the fetal liver of mice lacking RhoA in 
megakaryocytes specifically displayed larger and higher ploidy megakaryocytes as 
compared to control animals (Suzuki, Shin et al. 2013).  This increase in nuclear content 
provides the megakaryocyte with the ability to make an extensive high lipid-high protein 
membrane system called the IMS (Invaginated Membrane System) (Machlus and Italiano 
2013). The IMS is continuous with the plasma membrane and located throughout the 
cytoplasm of megakaryocytes, which allows it to serve as a reservoir for proplatelet 
formation (Schulze, Korpal et al. 2006, Machlus and Italiano 2013).  
Transcriptional Control of Megakaryocytes 
Several transcription factors are known to impact the differentiation of immature 
megakaryocytes into high ploidy megakaryocytes with a mature cytoplasm that can 
generate platelets. Gata-1 is a zinc finger protein that is expressed in megakaryocytes, 
erythrocytes, mast cells, eosinophils and sertoli cells (Crispino 2005). Gata-1 binds to 
DNA via its C-terminal zinc finger and binds to the cofactor FOG-1 via its N-terminal 
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zinc finger (Zheng and Blobel 2010). The binding of Gata-1 to FOG-1 allows Gata-1 to 
bind to (W)GATA(R) consensus sequences in the promoter of megakaryocyte specific 
genes that promote the differentiation of megakaryocytes (Evans, Reitman et al. 1988, 
Muntean and Crispino 2005). In order to delineate the role of Gata-1 in hematopoiesis in 
vivo, Gata-1 null mice were produced. It was found that the lack of Gata-1 is embryonic 
lethal at 10.5 dpi because of an anemia resulting from the apoptosis of erythroid 
precursors (Fujiwara, Browne et al. 1996). In order to further study Gata-1, a DNase I 
hypersensitivity site that regulates the Gata-1 promoter was deleted (McDevitt, Fujiwara 
et al. 1997). The mice (termed Gata-1low mice) were found to have very low expression 
of Gata-1 in megakaryocytes, yet the expression level in the erythroid lineage was 
sufficient to prevent apoptosis and embryonic lethality (Shivdasani, Fujiwara et al. 1997). 
This low level expression of Gata-1 caused an increase in proliferation and decrease in 
cytoplasmic maturation of megakaryocytes. An increase in the percentage of low ploidy 
as well as 64n ploidy megakaryocytes was noted (Shivdasani, Fujiwara et al. 1997, Vyas, 
Ault et al. 1999). Gata-1 is therefore an important transcription factor for megakaryocyte 
proliferation and polyploidization.   
 NF-E2 is a transcription factor that is expressed in erythrocytes and 
megakaryocytes (Romeo, Prandini et al. 1990). It is member of a family of transcription 
factors called the Cap’n Collar (CNC) transcription factors, which all contain a bzip 
(basic leucine zipper) domain for DNA binding and bind small MAF 
(musculoaponeurotic fibrosarcoma) proteins (Andrews, Erdjumentbromage et al. 1993, 
Igarashi, Kataoka et al. 1994). NF-E2 consists of a p45 subunit, which contains the bzip 
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domain that binds to MAFG or MAFK in megakaryocytes to regulate megakaryocyte 
gene expression (Lecine, Blank et al. 1998). The major function of NF-E2 in 
megakaryocytes is in the regulation of late cytoplasmic maturation and proplatelet 
formation (Shivdasani 1996, Lecine, Villeval et al. 1998). Several target genes have been 
examined such as thromboxane A2, β1 tubulin and Rab27b. Thromboxane A2 is a 
prothrombotic molecule located in megakaryocyte and platelet granules (Deveaux, 
Cohen-Kaminsky et al. 1997). β1 tubulin, a protein that comprises the microtubules in 
proplatelets, is another target gene of NF-E2 (Lecine, Italiano et al. 2000). NF-E2 null 
mice have low mRNA expression of β1 tubulin, but when NF-E2 is restored, β1 tubulin 
expression levels increase (Lecine, Italiano et al. 2000). Rab27b is a small RAS-like 
GTPase that is important for proplatelet formation and found to be upregulated by the 
binding of NF-E2 to its promoter (Tiwari, Italiano et al. 2003). The role of NF-E2 in 
thrombosis and proplatelet formation indicates that it is critical for the late maturation of 
megakaryocytes into platelet producing cells. Recognizing that none of the above factors 
are tissue specific, Hazony et al. argued that a combination of several non-tissue specific 
factors creates a specific transcription factor signature that is unique to megakaryocytes 
(Hazony, Lu et al. 2006).  
Thrombopoietin and Megakaryopoiesis 
Thrombopoietin (TPO) is a cytokine that is secreted from the liver and kidney 
(Sungaran, Markovic et al. 1997). The amino terminal of TPO contains the RBD domain 
(Ras Binding Domain), which allows it to bind to the c-mpl receptor on megakaryocytes 
(Bartley, Bogenberger et al. 1994). Stimulation of the c-mpl receptor by TPO is followed 
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by homodimerization of two c-mpl receptors and phosphorylation of the non-receptor 
tyrosine kinase Janus Kinase 2 (JAK2) on each receptor (Ezumi, Takayama et al. 1995, 
Drachman, Millett et al. 1999). Janus Kinase 2 phosphorylation is followed by 
phosphorylation of STAT transcription factors, which are then translocated to the nucleus 
where they regulate megakaryocyte gene expression (Bacon, Tortolani et al. 1995, 
Ezumi, Takayama et al. 1995). TPO has been found to promote the proliferation and 
differentiation of megakaryocytes (Broudy, Lin et al. 1995, Debili, Wendling et al. 1995). 
In vivo studies have shown that giving a TPO mimetic to non-human primates can 
increase platelet counts. Genetic deletion of TPO in mice results in a platelet count 
approximately 10% of normal and very small megakaryocytes that are decreased in 
number and ploidy (de Sauvage, Carver-Moore et al. 1996, Harker, Marzec et al. 1996). 
This suggests that TPO regulates megakaryocyte proliferation and differentiation, but not 
platelet production.  
The Role of Megakaryocytes in Producing Extracellular Matrix (ECM) Proteins 
Although megakaryocytes are best known for their function in platelet production, 
recent studies have explored their ability to regulate the highly dynamic bone marrow 
microenvironment. In 2014, Malara et al. studied the expression of bone marrow ECM 
proteins in megakaryocytes after myelosuppression of mice with the cytotoxic reagent 5-
fluorouracil (5-FU) or platelet depletion with a Gp1bα antibody (Malara, Currao et al. 
2014). All of the mice in this study recovered their platelet counts, but megakaryocytes 
from mice treated with 5-FU showed an upregulation of the ECM proteins laminin, type 
IV collagen and fibronectin (Malara, Currao et al. 2014). This shows that the expression 
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of ECM proteins is likely not related to platelet production, but is related to 
myeloablation. In support of the evidence that megakaryocytes play an important role in 
ECM production post-myeloablation, many studies have shown that bone marrow 
fibrosis is correlated with an increase in megakaryocyte number. For example, Gata-1low 
mice and mice that overexpress TPO in the hematopoietic cells have increased 
megakaryocyte number as well as bone marrow fibrosis and osteosclerosis (Yan, Lacey 
et al. 1995, Villeval, Cohen-Solal et al. 1997). It is believed that megakaryocytes play a 
central role in secreting cytokines as well as ECM and this contributes to the fibrosis and 
osteosclerosis seen in these animals.  
BCR-ABL Negative Myeloproliferative Neoplasms (MPN) 
MPNs are a group of cancers of the bone marrow that are characterized by the 
rapid proliferation of myeloid lineage cells and the potential outcome of bone marrow 
fibrosis with associated osteosclerosis. Initially, this group of diseases was seen as 
separate entities, but in the early 1900’s, several members of the scientific community 
began to notice similarities in the presentation and the cytology of the diseases. In 1951, 
Dr. William Dameshek published an editorial building on previous observations that 
MPNs were actually a set of related diseases. Dr. Dameshek acknowledged that patients 
present with proliferation of erythroblasts, megakaryocytes and granulocytes together and 
not one lineage on its own. He also noticed that there was an accompanying bone marrow 
fibrosis and splenomegaly that seemed to be occurring in each of the diseases. This led 
Dr. Dameshek to hypothesize that the MPNs are a group of diseases that are “closely 
interrelated” (Dameshek 1951). In addition, the theory by Dr. Theodore Boveri that 
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cancer is caused by chromosomal aberrations was supported when Dr. Peter Nowell and 
Dr. David Hungerford found that there was a chromosomal abnormality in Chronic 
Myelogenous Leukemia (CML), one type of MPN. This abnormality became known as 
the Philadelphia Chromosome, and was further described as a reciprocal translocation 
between chromosomes 9 and 2, which leads to expression of the BCR-ABL fusion 
protein. Studies examining females heterozygous at the Glucose-6-Phosphate 
Dehydrogenase (G6PD) and Phosphoglycerate Kinase (PGK) loci helped to determine 
that the stromal cell proliferation seen was reactive to the clonal proliferation of myeloid 
cells. In 2005, several laboratories published that the MPNs lacking the Philadelphia 
chromosome contain a gain of function mutation in JAK2 (Tefferi and Vainchenker 
2011). Other mutations that have been discovered in BCR-ABL negative MPNs are in 
genes encoding the TPO receptor c-mpl as well as the endoplasmic reticulum resident 
protein calreticulin. Mutations in the genes encoding JAK2, c-mpl and calreticulin all 
increase JAK-STAT signaling (Tefferi 2008, Vardiman, Thiele et al. 2009).  
The three types of BCR-ABL negative MPNs are Primary Myelofibrosis (PMF), 
Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Each type is 
distinguished from the others by histology, cytology, blood counts and mutation status. A 
hemoglobin >18.5 in men or  >16.5 in women along with the JAK2V617F or JAK2 exon 
12 mutation is indicative of PV although recognition of subnormal erythropoietin level as 
well as trilineage myeloproliferation in the bone marrow also points towards a diagnosis 
of PV (Vardiman, Thiele et al. 2009).  ET is a diagnosis of exclusion as any indication 
that the diagnosis could be due to another disease forfeits the diagnosis of ET (Vardiman, 
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Thiele et al. 2009). Without any evidence of another type of MPN or reactive 
thrombocytosis, a platelet count in humans of >450x109 platelets/L, a bone marrow 
biopsy showing an increase in the amount of mature megakaryocytes and the presence of 
a clonal marker such as JAK2V617F are indicative of ET (Vardiman, Thiele et al. 2009). 
The diagnosis of PMF relies on exclusion of other possible reasons for fibrosis, the 
presence of atypical megakaryocytes, the presence of a clonal marker such as 
JAK2V617F, increased LDH (lactate dehydrogenase), anemia, leukoerythroblastosis, and 
the existence of a palpable spleen (Vardiman, Thiele et al. 2009).  PMF can be diagnosed 
without fibrosis in a condition termed “prefibrotic PMF” which is demonstrated on bone 
marrow biopsy as increased marrow cellularity, granulocytic proliferation, and decreased 
erythropoiesis (Vardiman, Thiele et al. 2009). Both ET and PV have the potential to 
progress to myelofibrosis though post-ET myelofibrosis is rare (Vardiman, Thiele et al. 
2009).   
Upon visualization of bone marrow biopsies from patients with myelofibrosis, 
two types of fibers can be seen depending on the stage of the disease and the histologic 
staining method utilized. Reticulin fibrosis is a reversible reticulin fiber deposition that 
presents in early stage fibrotic disease (Thiele, Kvasnicka et al. 2005). Reticulin fibers are 
thin fibers composed of mainly type III collagen, but also consist of collagen type X, 
proteoglycans and glycosaminoglycans (Ushiki 2002). A silver impregnation method is 
used to stain reticulin fibers, which allows the silver molecules to bind to the 
glycoproteins of the reticulin fibers and indirectly stain the associated collagen (Gomori 
1937, Ushiki 2002). Collagen fibrosis presents in late stage fibrotic disease and has been 
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determined to be an indication of low prognosis (Thiele, Kvasnicka et al. 2005). The 
collagen fiber being referred to in “collagen fibrosis” is type I collagen which can be 
visualized in Hematoxylin & Eosin staining as a pink wavy matrix surrounding cells or in 
Masson trichrome stain as a green matrix surrounding cells (Ushiki 2002).  
In order to grade the bone marrow fibrosis, pathologists stain bone marrow biopsy 
samples for reticulin and collagen fibers. In 1971, Dr. Donald Bauermeister was the first 
to create a grading criteria for myelofibrosis which took into account reticulin fibrosis 
using silver stained patient samples as well as collagen fibrosis using the Masson 
Trichrome stain (Bauermeister 1971). He utilized 107 hematologically normal specimen 
and 14 specimen from patients with myelofibrosis of different etiologies (Bauermeister 
1971). Using a total of 6 grades, Dr. Bauermeister graded the specimen from 0 to 3+ with 
increasing coarseness and diffuseness of the reticulin fibers. The grade of 4+ was 
reserved for the presence of collagen fibrosis in addition to intersecting reticulin fibers 
(Bauermeister 1971).  
A more recent scale for bone marrow fibrosis was developed by a team of 
European hematopathologists and a foreign expert in 2005 with the goal of decreasing the 
number of grades to 4 and characterizing a normal level of reticulin fibrosis as grade 0 
(Thiele, Kvasnicka et al. 2005). The team evaluated 150 paraffin-embedded biopsy 
sections from the posterior iliac crest of patients with bone marrow fibrosis, most of 
whom were diagnosed with PMF (Thiele, Kvasnicka et al. 2005). The experts, 
individually and without knowledge of the clinical parameters or diagnosis of the patient, 
graded the bone marrow biopsy sections and a consensus was achieved in follow-up 
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meetings as a group. MF-0 (grade 0) was characterized as having a normal level of 
reticulin fibers that were scattered and had no intersections (cross-overs) (Thiele, 
Kvasnicka et al. 2005). MF-1 (grade 1) was characterized as having reticulin fibers 
situated in a “loose network” and containing some intersections. MF-2 (grade 2) was 
characterized as having “diffuse and dense” reticulin fibers with minimal and focal 
collagen fibrosis and osteosclerosis (Thiele, Kvasnicka et al. 2005). MF-3 was 
characterized as having “diffuse and dense” reticulin fibrosis with extensive intersections 
as well as widespread osteosclerosis and collagen fibrosis (Thiele, Kvasnicka et al. 2005). 
There was a 95% consensus in grading of the slides between pathologists with a high 
degree of reproducibility (Thiele, Kvasnicka et al. 2005).  
In addition to grading of bone marrow fibrosis, there have been several grading 
scales that primarily take into account clinical parameters of myelofibrosis in order to 
evaluate the prognosis of patients without grading bone marrow biopsies. One such 
grading scale is the International Prognostic Scoring System (IPSS), which places 
patients with myelofibrosis into low, intermediate-1, intermediate-2 and high-risk groups. 
Increased risk of mortality in this scoring system is correlated with increased age (>65 
years old), the presence of constitutional symptoms, decreased hemoglobin levels (<10 
g/dL), a high leukocyte count (>25x109 /l) and an increase in the number of circulating 
blast cells ( ≥1%)(Cervantes, Dupriez et al. 2009). When the IPSS was combined with the 
European Consensus for grading bone marrow fibrosis, it was found that the two together 
provide a better prognosis for patients (Gianelli, Vener et al. 2012).  
Myelofibrosis in MPN is believed to be a reactive process that is due to a clonal 
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proliferation of neoplastic cells (Jacobson, Salo et al. 1978, Mesa, Barosi et al. 2006). 
These proliferating cells are thought to have the ability to secrete factors that impact the 
proliferation of stromal cells leading to increased collagen secretion and bone marrow 
fibrosis. Transforming Growth Factor β-1 (TGFβ-1) is a secreted protein that can activate 
stromal cells to secrete collagen. Several studies have shown the importance of TGFβ-1 
in regulating bone marrow fibrosis (Ghosh, Quaggin et al. 2013). In a study by Komura et 
al., a retrovirus was used to transduce the bone marrow cells of WT (Wild Type) and 
TGFβ-1 null mice with TPO.  The transduced bone marrow cells were transplanted into 
lethally irradiated WT mice and fibrosis was evaluated in the bone marrow four months 
after transplantation. Bone marrow fibrosis was only detected in recipient mice that 
received bone marrow from WT mice and not from TGFβ-1 -/- mice (Chagraoui, Komura 
et al. 2002). In another study by Zingariello et al., Gata-1low mice were treated with the 
TGFβ-1 inhibitor SB431542 and evaluated for bone marrow fibrosis. They found that 
SB431542 was able to reduce the bone marrow fibrosis seen in the Gata-1low mice 
(Zingariello, Martelli et al. 2013). These animal studies indicate a causative role for 
TGFβ-1 in the development of bone marrow fibrosis. A human study performed by Bock 
et al. showed an increase in TGF-β1 mRNA expression in the megakaryocytes of patients 
with BCR-ABL negative MPNs (Bock, Loch et al. 2005). However, this upregulation of 
TGFβ-1 was not correlated with the extent of bone marrow fibrosis (Bock, Loch et al. 
2005).  
Platelet Derived Growth Factor (PDGF) is another protein that has been 
implicated in causing the fibrosis seen in MPN. PDGF is widely expressed and has been 
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shown to increase the proliferation of fibroblasts. In a study by Pattengale et al., platelet 
poor plasma and urine from patients with PV, ET and PMF were collected and examined 
for PDGF expression using an ELISA (Gersuk, Carmel et al. 1989). PDGF was found to 
be increased in the platelet-poor plasma of patients with PMF and ET, but not in patients 
with PV (Gersuk, Carmel et al. 1989). In another study by Bock et al., mRNA expression 
of PDGF was measured in the bone marrow cells of PMF patients and found to be 
increased as compared to patients with pre-fibrotic PMF, which suggests that PDGF 
could be used as a marker of advanced stage PMF (Bock, Loch et al. 2005). 
 Lysyl Oxidase (LOX) is a monoamine oxidase that has the ability to modify 
specific lysines in soluble collagen and elastin fibers and change them into semi-
aldehydes that are reactive. This causes the formation of insoluble and cross-linked 
collagen and elastin. LOX is therefore an important molecule for ECM stabilization 
(Kagan and Trackman 1991). LOX null animals die either just before gestation or just 
after birth due to aortic aneurysms (weakened aortic wall) (Hornstra, Birge et al. 2003). 
The ability of LOX to impact fibrosis has been studied in several systems including lung, 
heart and kidney and LOX has been shown to be upregulated in the presence of TGFβ-1 
(Rosenbloom, Ren et al. 2016). In 2012, our lab published a study showing that Gata-
1low mice have increased LOX expression in their megakaryocytes. In addition, when 
the mice were treated with the LOX inhibitor BAPN, decreased bone marrow fibrosis 
was revealed compared to Gata-1low mice treated with a vehicle (Eliades, 
Papadantonakis et al. 2011). In addition, it was shown that patients with MPN have 
increased LOX expression in the bone marrow as well as in the serum (Eliades, 
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Papadantonakis et al. 2011). These studies suggest that LOX plays an important role in 
myelofibrosis.  
Megakaryocytes have been implicated in being the cause of bone marrow fibrosis 
and osteosclerosis. Patients with post-PV fibrosis, post-ET fibrosis and PMF all have 
increased megakaryocytes upon bone marrow biopsy despite differences in the 
morphology and maturity of the megakaryocytes (Vardiman, Thiele et al. 2009). Post-PV 
myelofibrosis and post-ET myelofibrosis are characterized by an increase in the number 
of megakaryocytes at all maturity stages (Vardiman, Thiele et al. 2009). In contrast, PMF 
megakaryocytes are characterized as atypical and less mature, though still increased 
(Vardiman, Thiele et al. 2009). Other support for a role of megakaryocytes in the 
pathophysiology of bone marrow fibrosis and osteosclerosis comes from experiments in 
animals. The Gata-1low mice and TPO overexpressing mice have an increase in the 
number of megakaryocytes and they both display increased bone marrow fibrosis and 
osteosclerosis (Yan, Lacey et al. 1996, Vannucchi, Bianchi et al. 2002). In addition, the 
megakaryocytes have been implicated in secreting TGFβ-1, PDGF and LOX in order to 
contribute to bone marrow fibrosis (Papadantonakis, Matsuura et al. 2012). Further 
studies are needed to elucidate the role that megakaryocytes play in regulating bone 
marrow fibrosis as well as in the evolution and cause of osteosclerosis.  
Therapy in BCR-ABL Negative MPNs 
 The treatment of patients with MPNs is dependent on risk assessment in each 
individual patient. For PV, while all patients are treated with aspirin, only patients that 
are at low risk for thrombosis are treated with phlebotomy and only high risk patients 
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with splenomegaly or a high risk of thrombosis is treated with a cytoreductive agent such 
as hyroxyurea (Passamonti 2012).  All ET patients are also treated with aspirin. ET 
patients at high thrombotic risk are treated with cytoreductive therapy such as 
hyrdorxyurea or anagrelide. In post-ET and post-PV myelofibrosis as well as PMF, 
patients that are considered low risk and intermediate-1 risk are only treated for their 
constitutional symptoms. Patients in the intermediate-2 or high-risk group are treated 
with allogeneic bone marrow transplantation unless they are ineligible. If ineligible due 
to age, the presence of massive splenomegaly or severe constitutional symptoms, patients 
continue to have their symptoms treated and are candidates for investigational drug 
treatment.  
 Several drugs are being investigated that target the clonal cells by inhibiting JAK2 
signaling. The most well studied drug and the only JAK2 inhibitor approved in the 
United States for treatment of patients with Primary Myelofibrosis is Ruxolitinib (Geyer 
and Mesa 2014). Ruxolitinib has been found to reverse splenomegaly as well as reduce 
symptoms and cause a 42% reduction in the risk of death when compared to the best 
available treatment (Geyer and Mesa 2014). Though still under investigation, Ruxolitinib 
has also been found to decrease spleen size in patients with PV (Geyer and Mesa 2014).  
These favorable outcomes in Ruxolitinib treatment have lead to an interest in using the 
drug before allogeneic bone marrow transplantation in order to reduce the risk of 
complications and mortality in patients with myelofibrosis (Yacoub, Odenike et al. 2014).  
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Overview Hypothesis and Rationale 
Several aspects of myelofibrosis need further exploration. This relates to (1) the role 
of megakaryocytes in regulating the extracellular matrix and bone marrow fibrosis and 
(2) the evolution of osteosclerosis in PMF. Previous studies have shown that Egfl7 binds 
the LOX enzyme at its catalytic domain and inhibits its ability to cross-link collagen and 
promote bone marrow fibrosis. In collaboration with Dr. Shinobu Matsuura and Dr. 
Hector Lucero, I sought to examine the hypothesis that Egfl7 inhibits myelofibrosis by 
assessing the phenotype of Gata-1low mice with increased expression of Egfl7 in the 
megakaryocytes. In addition, it was found that female Gata-1low mice have a tendency 
towards more trabecular bone formation within the marrow space at a younger age than 
male Gata-1low mice. I sought to further explore the hypothesis that sex plays a role in 
the progression of the myelofibrotic disease in the Gata-1low mice.   
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Illustration 1: Differentiation of HSCs into Mature Blood Cells.  
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CHAPTER II. METHODS 
Animal Models 
Gata-1low Mice 
The Gata-1low mice (ΔneoΔHS strain) used in these studies were a gift from Dr. John 
Crispino of Northwestern University and previously described (Vannucchi, Bianchi et al. 
2002). The Gata-1low mouse colony was expanded and maintained in the housing 
facilities of the Boston University Medical Campus (BUMC). This line is on a C57BL6/J 
background.  
Generation of PF4-Egfl7/Gata-1low transgenic mice 
The following steps were taken by Dr. Shinobu Matsuura in our lab in order to generate 
the PF4-mEgfl7-Globin construct. The mouse 1.4 kb Egfl7-pcDNA3 plasmid gifted from 
Dr. Virginie Mattot (Institut de Biologie de Lille) was digested with the XhoI and EcoRI 
restriction enzymes. The released mEgfl7 fragment was cloned into a 1.1 kb rat PF4-
Globin plasmid generated by Dr. Katya Ravid (Ravid, Beeler et al. 1991) and linearized 
using NotI and NcoI restriction enzymes. This PF4-mEgfl7-globin plasmid was amplified 
using the Qiagen Plasmid Midi Kit (catalog # 12143) and digested with AatII and SwaI 
restriction enzymes in order to release the PF4-mEgfl7-globin fragment from vector 
sequences. The PF4-mEgfl7-globin fragment contains mEgfl7 located downstream of a 
1.1 kb rat PF4 promoter and upstream of a 1.0 kb fragment of the 3’ region of the human 
β-globin gene. 
The following steps were taken by Greg Martin of the Boston University Transgenic Core 
to generate the PF4-mEgfl7/Gata-1low founders and Dr. Rongjuan Mi in our lab to 
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screen founders for insertion of the PF4-mEgfl7-globin fragment. PF4-mEgfl7 DNA 
fragments were microinjected into the pronuclei of one-cell homozygous Gata-1low 
mouse fertilized oocytes. The injected fertilized oocytes were implanted into a 
pseudopregnant FVB mouse foster mice. Screening of transgenic founders for insertion 
of the PF4-mEgfl7-globin DNA fragment using genomic tail DNA, as described below, 
resulted in confirmation of insertion of the fragment in founders #2 and #19. Founder #2 
and #19 lines were bred to homozygosity and maintained in the housing facility of the 
Boston University Medical campus. The Boston University Institutional Animal Care and 
Use Committee (IACUC) approved all procedures involving the use of mice in these 
studies. Wild type C57BL6/J control mice were ordered for all studies from Jackson 
Laboratories (Stock No: 000664).  
DNA Analysis 
Tail-DNA Isolation 
A small piece of mouse-tail was cut and DNA was isolated according to the 
manufacturer’s protocol using the Qiagen DNeasy Blood and Tissue Kit (catalog # 
69504). The resulting DNA flow-through was stored at -20°C. 
Quantitative Real Time Polymerase Chain Reaction  
The Epidermal Growth Factor Like 7 (Egfl7) gene was screened in PF4-Egfl7/Gata-1low 
mice using genomic tail DNA. Each reaction included 3 µl of ddH2O, 1 µl of genomic 
tail DNA, 5 µl of TaqMan Gene Expression Master Mix (ThermoFisher Scientific, 
catalog # 4369016), 0.5 µl of the A2bAR primer-probe set (Mm00439768) and 0.5 µl of 
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Egfl7 primer-probe set (catalog # Mm00618004) for a total reaction volume of 10 µl. 
Each reaction was performed in one well of a 384 well plate on a ViiA™ 7 Real Time 
PCR machine (ThermoFisher Scientific, catalog # 4453534).  
Bovine Serum Albumin (BSA) Density Gradient Isolation of Mouse Bone Marrow 
Megakaryocytes 
Mouse femurs and tibias were flushed with Catch buffer (10x HBSS, 3.8% sodium 
citrate, 10X adenosine theophylline (1.0 mM adenosine, 20 mM theophylline), 10% 
Bovine Calf Serum in ddH2O) with a 25 G needle into a 50 mL conical tube. Bone 
marrow cell suspensions were centrifuged at 1200 rpm for 5 minutes at 4°C.  Cell pellets 
were resuspended in CATCH buffer and filtered through a 100 µm filter into a new 50 
mL conical tube. Cell suspensions were centrifuged at 1200 rpm for 5 minutes at 4°C. 
The cell pellets were resuspended in 5 mL of IMDM media supplemented with 10% FBS 
(catalog # 16000-044, Lot#1680759, Gibco), 1% Penicillin-Streptomycin (catalog # 30-
001-C1, Corning Cellgro) and 1% L-glutamine (catalog # 25030-081, Gibco). 
Thrombopoietin (TPO) (human PEG-rhMGDF, gift from Kirin Pharma Company) was 
added to the cell suspension at a final concentration of 25 ng/mL.  Bone marrow cells 
were added to a six well dish and incubated for four days at 37°C in 5% CO2. The 
supernatant was collected as well as the lightly attached cells by washing the dish with 
Calcium and Magnesium free 1x PBS. The cell suspension was centrifuged at 1200rpm 
for 5 min at 4°. The cell pellet was resuspended in serum-free IMDM (1% Penicillin-
Streptomycin and 1% L-glutamine) and added to a BSA density gradient. The BSA 
density gradient consisted of 1.5 mL of 3% BSA (catalog # BP9704-100, Fisher) in 1x 
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PBS on the bottom and 1.5 mL of 1.5% BSA in 1x PBS at the top in a 15 mL conical 
tube. The resuspended cells were added to the top of the BSA density gradient and 
megakaryocytes were allowed to drift to the bottom for 30 minutes at room temperature. 
Next, the supernatant was aspirated leaving behind 1 ml of 3% BSA. Remaining cells 
within the 3% BSA that was left behind were washed with 1x PBS and centrifuged at 
1200 rpm for 5 minutes at 4°C. Cells were resuspended in 1 mL of serum free IMDM and 
passed through another BSA density gradient and incubated for 30 minutes at room 
temperature. Next, the supernatant was aspirated leaving behind 1 ml of 3% BSA.  
Remaining cells were washed with 1x PBS and centrifuged at 1200 rpm for 5 minutes at 
4°C. Cells were resuspended in calcium and magnesium free 1x PBS cells and counted 
for purity based on large cell: small cell ratio. For supernatant experiments, the 
megakaryocytes were plated overnight in serum-free media at 37°C in 5% CO2 and the 
supernatant was concentrated in a centricon 10 tube (catalog # 4205, Millipore) at 5,000 x 
g for 30 minutes at 4°C. The supernatant was frozen at -80°C until further use.  
mRNA Analysis 
RNA Isolation 
Pelleted primary megakaryocytes were resuspended and lysed in 350 µl of Qiagen Buffer 
RLT plus (catalog# 1053393, Qiagen) and the cell lysate was vortexed and added to a 
Qiashredder column (catalog# 79656, Qiagen) and centrifuged at 13,000 rpm for 3 
minutes for homogenization. The RNA was purified using the Qiagen RNeasy Plus Mini 
Kit (catalog# 74134, Qiagen) according to the manufacturer’s protocol. The 
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concentration of the RNA was quantified using a Nanodrop 2000. RNA was stored at -
80°C. 
Reverse Transcription 
RNA was reverse transcribed into cDNA using Qiagen’s Quantitect Reverse 
Transcription kit (catalog # 205311, Qiagen) according to the manufacturers protocol and 
between 80 and 100ng of RNA was used per reaction. The total reaction volume was 
20µl. The cDNA was stored at -20°C. 
Quantitative Realtime PCR (qRT-PCR) 
A volume of 1µl of reverse transcribed cDNA was added at a volume of 3 µl of ddH2O, 
5µl of TaqMan Gene Expression Master Mix (catalog # 4369016, ThermoFisher 
Scientific), 0.5 µl of the GAPDH-VIC primer-probe set for normalization of DNA 
amount (Mm00439768, Applied Biosystems) and 0.5 µl of experimental primer-probe set 
for a total reaction volume of 10 µl. Each reaction was performed in one well of a 384-
well plate on a ViiA™ 7 Real Time PCR machine (catalog# 4453534, ThermoFisher 
Scientific). The following experimental primer-probe sets from Applied Biosystems were 
used: Egfl7-FAM (Mm00618004), Gata-1-FAM (Mm00484678-m1), and Lox 
(Mm00495386_m1) and Itga2b CD41 (Mm00439768_m1). 
HEK (Human Embryonic Kidney) Cell Transfection  
HEK cells were obtained from ATCC. The cells were plated at 1x105 cells per well in 
3mL of DMEM with 10% FBS and 1% penicillin/streptomycin. After two days, cells 
were transfected with no plasmid (just water), 10 µg of pcdna3 plasmid and 10 µg of 
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Egfl7-pcdna3 plasmid (gifted from Virginie Mattot (Institute de Biologie de Lille) by the 
following calcium chloride transfection method: Plasmid DNA was added to an 
eppendorf tube with 500 µl of calcium chloride solution (250 mM CaCl2, 3.4 mM Hepes, 
pH ~7.05-7.10). Next, 500 µl of Hbs buffer (274 mM NaCl, 10 mM KCl, 1.4 mM 
Na2HPO4, 42 mM Hepes, 0.2% Dextrose, pH ~7.05-7.10) was added to a 15 mL conical 
tube. The Hbs buffer was bubbled with a 5 mL pipette and then added 1 drop per second 
to the calcium chloride solution with a 200 mL pipette. The solution was incubated at 
room temperature for 20 minutes. Finally, the DNA/CaCl2/Hbs solution was added drop 
by drop to a 100 mL dish with 10 mL media and the dish was tilted side to side for 
mixing. The next day, the media was replaced with new media. For supernatant 
experiments, the HEK cells were incubated with serum-free media overnight and then the 
supernatant was concentrated in a centricon 10 tube (catalog # 4205, Millipore) at 3,220 x 
g for 30 minutes at 4°C. The supernatant was frozen at -80°C until further use. 
Western Blot Analysis 
Cell Lysate 
Differentiated primary megakaryocytes or transfected HEK cells were centrifuged at 4°C 
for 10 minutes at 1200 rpm and 1x SDS buffer (0.0625 Tris-HCl (pH=6.8), 2% sodium 
dodecyl sulfate, 10% glycerol, 50 mM dithiothreitol and a pinch of bromophenol blue) 
was added to each pellet. The pelleted cells were pipetted up and down and pushed 
through a 25 G needle three times. The lysate was boiled at 95°C for 10 minutes. Protein 
was electrophoresed on a 10% SDS polyacrylamide gel and run at 80 mV until the dye 
front reached the end of the gel. The proteins were transferred from the gel to an 
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ImmunBlot PVDF membrane (catalog # 162-0177, BioRad) at 4°C overnight in transfer 
buffer (3.03g of Tris-HCl, 14.4g of glycine, 200 mL methanol up to 1L with ddH2O) at 
35 mV. PVDF membranes were incubated in 0.1% ponseau-S stain (w/v) in 5% acetic 
acid v/v (catalog # P-3504, Sigma) for 5 minutes and rinsed for thirty seconds in ddH20 
in order to visualize the proteins on the membrane. The membrane was rinsed and 
incubated in blocking buffer (5% milk in 0.1% TBS-T) for 1 hour at room temperature. 
Next, the membrane was incubated at 4°C while rocking overnight in rat anti-mouse 
Egfl7 (catalog # MAB3089, R&D Systems) at a dilution of 1:1000 in blocking buffer. 
The membrane was washed with 1x TBS-T three times for 10 minutes each and the 
membrane was incubated in HRP conjugated anti-rat secondary antibody (catalog # 
70775, Cell Signaling) at a dilution of 1:5000 in blocking buffer. The membrane was 
washed three more times at 10 minutes per wash in 1x TBS-T.  For visualization of 
protein, Millipore Immobilon Western Chemiluminescent Horseradish Peroxidase 
Substrate (catalog # WBKLS0500, Millipore) was used and the signal was developed 
using autoradiography film (catalog # E3012, Denville). 
Supernatant 
SDS sample buffer was added to supernatants from WT, Gata-1low, #19-PF4-
Egfl7/Gata-1low and #2-PF4-Egfl7/Gata-1low mice and boiled for 10 minutes at 95°C. 
Western blot was done for Egfl7 using the 18F7 antibody as previously described. 
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Flow Cytometry 
Bone Marrow Isolation For Flow Cytometry Analysis 
Bone marrow cells were collected by flushing femurs and tibias with a 25 G needle using 
Macs buffer (0.5% fatty acid free BSA, 2 mM EDTA in Ca2+ and Mg2+ free Dulbecco’s 
Phosphate Buffered Saline (DPBS), pH 8). Cell suspensions were centrifuged at 1200 
rpm (Eppendorf Centrifuge 5810R) for 5 minutes at 4°C. Cell pellets were resuspended 
and cells were incubated at room temperature in 4 mL of red blood cell lysis buffer (Tris 
0.205g, NH4Cl 0.75g dissolved in 100 ml of H2O, pH 7.2). Cells were washed in 20 mL 
of MACS buffer, strained through a cell strainer and centrifuged at 1200 rpm for 5 
minutes at 4°C. Next, the cells were resuspended in 10 mL of MACS buffer and 
centrifuged at 1200 rpm for 5 minutes at 4°C. 
Bone Marrow Megakaryocyte Analysis 
Bone marrow cell number was adjusted to 107 cells/mL of MACS buffer for experimental 
samples and 106 cells/mL for control samples. Antibodies were added at the following 
dilutions. In order to stain megakaryocytes, anti-mouse CD41-FITC (catalog # 11-0411-
82, ebioscience) diluted 1:100 was added. In order to stain dead cells, Zombie aqua dye 
(catalog # 423101, biolegend) was used. A master mix of biotin conjugated mature blood 
cell lineage markers from eBioscience. The following antibodies were used as biotin 
conjugated mature blood cell lineage markers: anti-mouse cd3ε (clone #:145-2C11) 
diluted 1:200 for T-cells, anti-mouse/human CD45-R B220 (catalog # 13-0452-75) 
diluted 1:200 for B cells, anti-mouse cd11b (catalog # 13-0112-75) diluted 1:200 for 
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myeloid cells, anti-mouse Ly-6G Gr-1 (catalog # 13-5931-75) diluted 1:200 for 
granulocytes and anti-mouse Ter119 (catalog #13-5921-75) diluted 1:200 for 
erythrocytes. Tubes were incubated in the dark at 4°C for 30 minutes. Cells were washed 
with MACS buffer and resuspended in 1:200 PE Cy5 conjugated streptavidin (catalog # 
15-4317-82, ebioscience) and incubated in the dark at 4°C for 30 minutes.  Cells were 
washed again and resuspended in 500 µl of Macs buffer and data was acquired and 
analyzed on the LSRII flow cytometer. 
Megakaryocyte Ploidy Analysis 
Bone marrow cell number in the cell pellet was adjusted to 2x107 cells/mL of Macs 
buffer. For FITC anti-mouse CD41 staining, 1 mL of cells (2x107 cells) was used, and for 
Rat IgG2bΚ Isocontrol FITC staining 0.5 mL of cells (1x107 cells) was used. Rat IgG2bΚ 
Isocontrol FITC (catalog # 11-403182, eBioscience) and CD41-FITC (catalog # 553848, 
BD Pharmingen) were added to control and experimental tubes at a dilution of 1:200. 
Cells were incubated in the dark at 4°C for 30 minutes. After incubation, cells were 
transferred to polystyrene tubes and 3 mL of Macs buffer was added to the cells followed 
by centrifugation at 1200 rpm for 5 minutes at 4°C. Cells were fixed with 70% Ethanol 
by adding one drop per second of ethanol to cells while gently vortexing. The cells were 
washed two times with DPBS without magnesium and calcium by centrifuging at 1200 
rpm for 5 minutes at 4°C. Ribonuclease A from bovine pancreas (catalog # R5125, 
Sigma) at a concentration of 0.1 mg/mL and propidium iodide (catalog # P1304MP, 
Invitrogen Molecular Probes) at a concentration of 0.05 mg/mL were added to the cells 
15 minutes before data acquisition and analysis on the Facscalibur Flow Cytometer.  
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Peripheral Blood Platelet Count 
Blood isolated by cardiac puncture or retro-orbital bleeding was placed in a 1.3 mL 
EDTA tube (catalog # NC9414041, Fisher) and analyzed using the hemavet multispecies 
hematology analyzer. 
Spleen Size 
The body weight of the mice was recorded followed by removal of the spleen. The spleen 
was separated from the pancreas and surrounding fat and weighed on an analytical 
balance. Spleen size was calculated as a ratio of the spleen weight (mg) to body weight 
(g) of the mice. 
Histology 
Tissue Fixation, Processing, Embedding, Sectioning, Deparaffinization and Dehydration 
Femurs were isolated from mice by cutting distal to the knee joint and proximal to the hip 
joint. Muscles were removed and femurs were fixed in 4% paraformaldehyde (J.T Baker, 
catalog # 5898-07) made in 1x PBS. For chapter III of this thesis, femurs were processed, 
embedded and sectioned by AML laboratories (http://www.amllabs.com) for three of the 
WT, three of the Gata-1low, three of the #19-PF4-Egfl7/Gata-1low and three of the #2-
PF4-Egfl7/Gata-1low mice. For the remaining samples in chapter III of this thesis (two 
WT, four Gata-1low, one #19-PF4-Egfl7/Gata-1low and one #2-PF4-Egfl7/Gata-1low 
mice) and for all of the samples in chapter IV of this thesis, tissue sections were prepared 
according to the following protocol: Femurs were decalcified in 0.5 M 
ethylenediametetraacetic acid disodium dehydrate (EDTA) (catalog # AB500, American 
bioanalytical) for five days at 4°C. The femurs were transferred to 70% ethanol and then 
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processed on a Leica ASP 300 tissue processor with a vacuum using the following 
protocol in the laboratory of Dr. Louis Gerstenfeld: 1 hour through each of the following 
in sequence: 70% ethanol, 80% ethanol, 2 times 95% ethanol, 3 times 100% ethanol, 3 
times xylene. These steps were followed by 3 changes of paraffin at 60°C after 1 hour, 
1.5 hours and 1.5 hours all at room temperature, except paraffin steps which were done at 
60°C. Samples were embedded with the condyles facing down, sectioned at a thickness 
of 5 µM on a Leica microtome and transferred to Thermoscientific Colorfrost Plus slides 
(catalog # 6776214, Fisher). The slides were deparaffinized using the following protocol 
in all staining methods, except immunohistochemistry: 5 minute dips repeated 2 times of 
Xylene, 5 minute dip of 100% ethanol, 5 minute dips repeated 2 times of 95% of ethanol, 
5 minute dip of 85% ethanol, 5 minute dip of 75% of ethanol and 5 minute dip of 1xPBS 
for Hematoxylin and Eosin (H&E) staining or ddH2O for reticulin staining. The slides 
were dehydrated using the following protocol for all staining protocols, except the TRAP 
staining protocol: 2 second dips repeated 10 times of 95% ethanol, 2 second dips repeated 
10 times of 100% ethanol and 2 minute dips repeated 2 times of xylene. 
Reticulin Staining 
The slides were heated to 60°C, deparaffinized and incubated in acidified 0.5% 
potassium permanganate (catalog # PPD500, Scytek) for 5 minutes which produced a 
color change in the sections from clear to purple. The slides were washed with ddH2O 
and incubated in 5% oxalic acid (catalog # 658537, Sigma), until clear again. The slides 
were washed in distilled water and placed in ferric ammonium sulfate sensitizing solution 
(catalog # FAS999, Scytek) for 10 minutes. The slides were washed in running tap water 
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for 5 minutes and dipped in silver solution 14 times for 4 seconds per dip. The 
preparation of the silver solution involved making 20 mL of 10% silver nitrate solution 
(catalog # S8157, Scytek) in ddH2O in a 50 mL conical tube and adding ammonium 
hydroxide drop by drop until clear again followed by 20 mL of 3% sodium hydroxide 
(catalog # AB01916-00500, American bioanalytical). Ammonium hydroxide (catalog # 
H205840010, Acros Organics) was added once again until a fine black precipitate 
remained in solution. The solution was poured into a 500 mL acid-washed beaker and 
made up to 200 mL with ddH2O.  The slides were dipped in three changes of dH2O and 
reduced in 4% formaldehyde (catalog # BP531-25, Fisher) made in ddH2O until the 
tissue sections turned gray black. The slides were washed in ddH2O for 5 minutes and 
toned using 0.5% gold chloride (catalog # GCB500, Scytek) for 1 minute, rinsed in 
distilled water, and fixed in 5% sodium thiosulfate solution (catalog # S-6672, Scytek) 
for 1 minute followed by another wash in running tap water for 5 minutes. The slides 
were incubated in fast red stain (catalog #, NFS125, Scytek) for five minutes, dehydrated 
and coverslipped, as described above.   
Reticulin Fiber Quantitation  
Image J (Done in collaboration with Dr. Hector Lucero)- Individual images were 
acquired in the SPOT 5.0 Software at 200X and the images were merged using Adobe 
Photoshop CS5 to create three panoramic views of the mid-diaphyseal regions of each 
femur. One image from the medullary space of each panoramic view was opened up in 
Image J, transformed into an RGB stack and the threshold was set to 0-150 for fixed 
thresholding. For manual thresholding, the threshold was changed on each individual 
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image to a level that allowed for visualization of reticulin fibers with the least amount of 
background present. If no reticulin fibers were seen, the threshold was set to a level just 
above when background began to be visualized. After thresholding, images were 
transformed into a binary image and integrated density measurements were normalized to 
the area of the bone analyzed and graphed to compare WT, Gata-1low and PF4-
Egfl7/Gata-1low mouse reticulin fiber staining. Since one image was created per 
panoramic view, 3 panoramic views were used per femur and 3 sequential femur sections 
were analyzed for each animal, for a total of 9 images used per animal for Image J 
analysis. 
Pathologic Criteria-Experimental samples included WT, Gata-1low, #19-PF4-
Egfl7/Gata-1low and #2-PF4-Egfl7/Gata-1low mice. Three sequential femur sections 
were analyzed per animal and three panoramic views of the mid-diaphyseal region per 
femur were used for grading. Between 6 and 13 individual images were acquired in the 
SPOT 5.0 Software at 20X and merged using Adobe Photoshop CS5 to create each 
panoramic view. In total, 9 panoramic views of the mid-diaphysis were analyzed per 
animal, which were each made up of between 54 and 117 individual images. The number 
of images used depends on the number of images needed to create a panoramic view. The 
grading numbers (between 1 and 4) were averaged across the three panoramic views 
taken for each blinded femur section. I evaluated the pathologic grading recognizing the 
natural individual bias of what one considers as constituting a certain pathological grade. 
The grading criteria included the following: 
1=no staining 
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1.5= minimal staining 
2=low staining near endosteum and low staining in medullary space. 
3=high staining near endosteum and low staining in the medullary space. 
4=high staining near endosteum and high staining in the medullary space.  
 
H&E Staining 
Slides were heated in a 60°C oven and deparaffinized. Slides were placed in Hematoxylin 
(catalog # 22-220-109, Fisher Healthcare) for 4 minutes and washed in dH2O 
continuously for 5 minutes. Following staining with Hematoxylin, slides were briefly 
dipped in Eosin stain (catalog # HT110132, Sigma) eight times. Next, slides were 
dehydrated as described above. The coverslips were placed on the slides over the tissue 
sections using cytoseal 60 (catalog # 8310-4, Richard Allan Scientific) and dried in the 
fume hood for 1 hour before visualization.  
Megakaryocyte Number Analysis by In Situ Analysis 
Femur- The H&E stained slides were blinded by Dr. Shinobu Matsuura. Images were 
acquired in the SPOT 5.0 Software at 200X in randomly selected areas of the mid-
diaphysis. Five pictures were taken per H&E stained tissue section in three femur 
sections per mouse. Megakaryocytes were counted in 200x high power fields (hpf). 
TRAP Staining and Cell Quantitation 
Deparaffinized slides were incubated in TRAP staining solution (500 mg naphtol from 
Sigma, 2.2 mL N,N-dimethyl formamide from Sigma, 40 mL tris acetate buffer from 
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Sigma, 80mg fast red LB salt from Sigma, 160 mg sodium tartrate from Sigma, 3 drops 
of 10% MnCl2; filtered into a glass coplin jar and heated to 37°C ) at 37°C for 25 min, 
washed in ddH2O 4 times and counterstained by dipping the slides once in Gill #2 
hematoxylin stain (catalog # GHS232, Sigma). The slides were washed once again in 
running tap water 4 times and incubated in 1% lithium carbonate for 30 seconds, rinsed 
once in ddH2O and air dried before being coverslipped.   
X-Radiation 
Mouse femurs were scanned with a Leica ASP 300 X-Ray machine in the lab of Dr. 
Gerstenfeld lab with the following settings: Shelf set in the middle slot, time 40s and 
voltage 30kV. 
Statistical Analysis 
GraphPad Prism 4 was used for all statistical analyses in this thesis. To compare two 
means, a student’s unpaired two-tailed t-test was used and a one or two-way analysis of 
variance (ANOVA) was performed to compare greater than two means. The post-hoc test 
employed with the ANOVA was a bonferonni multiple comparisons test. The α 
significance level utilized was 0.05.  
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CHAPTER III: THE IMPACT OF EGFL7 ON MYELOFIBROSIS 
Background 
Egfl7 and Endothelial Cell Proliferation 
Egfl7 is a secreted protein that is involved in vascular development and 
remodeling. The in situ expression pattern of Egfl7 is mainly restricted to the 
endothelium in embryonic and adult tissues (Fitch, Campagnolo et al. 2004). Increased 
levels of Egfl7 is detected in highly vascularized adult organs such as the lung, kidney 
and heart as well as in the uterus during pregnancy as compared to other organs such as 
the intestine, thymus and liver (Fitch, Campagnolo et al. 2004). In addition, protein 
expression of Egfl7 has been detected in HUVECs (Human Umbilical Vein Endothelial 
Cells) and in BAECs (Bovine Aortic Endothelial Cells) (Fitch, Campagnolo et al. 2004). 
Upregulation of in situ mRNA expression of Egfl7 occurs after ferric chloride injury of 
mouse carotid arteries and balloon injury in the ascending aorta of rats (Campagnolo, 
Leahy et al. 2005). In situ Egfl7 mRNA expression has also been localized to endothelial 
cells in human atherosclerotic plaques (Campagnolo, Leahy et al. 2005). These studies 
suggest that Egfl7 is primarily expressed during times of extensive endothelial cell 
proliferation.  
Egfl7 and Cancer 
Angiogenesis is important for the growth and metastasis of cancer cells. Several studies 
have supported a role for Egfl7 in solid tumor growth and invasion, some describing 
Egfl7 to be positively correlated with cancer progression and others describing Egfl7 as 
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negatively correlated with cancer progression. In situ Egfl7 mRNA expression was 
analyzed in breast cancer tumor sections and found to be higher in tumors relative to 
normal breast tissue. This increase in Egfl7 expression was found to be correlated with 
favorable prognostic factors such as a decreased Scarf-Blood-Richardson (SBR) score, 
estrogen receptor positivity and a lack of lymph node invasion (Philippin-Lauridant, 
Baranzelli et al. 2013). Also, Huang et al. examined Egfl7 in glioma versus normal brain 
tissue sections by immunohistochemistry (IHC) and found that Egfl7 is upregulated in 
glioma tissue sections as compared to normal brain tissue and this upregulation is 
correlated with pathological tumor cell invasion. When the glioma tumor cells were 
transduced with a retroviral construct encoding Egfl7 and then implanted into the fat pad 
of WT mice, the mice had larger tumors with a greater likelihood of metastasizing to the 
lung as compared to cells transduced with a control virus (Delfortrie, Pinte et al. 2011). 
Egfl7 mRNA and protein were found to be upregulated in Hepatocellular Cancer (HCC) 
tumors as well. The extent of Egfl7 expression correlated with the amount of metastasis 
and a poorer prognosis in patients (Wu, Yang et al. 2009). In addition, treatment of HCC 
cell lines with Egfl7 SiRNA decreased the ability of the cells to migrate in transwell and 
wound closure migration assays. The group further studied whether EGF receptor 
(EGFR) signaling could be impacting the ability of the HCC cells to migrate and found 
that cells with decreased Egfl7 expression due to treatment with Egfl7 SiRNA had 
decreased cytoskeletal reorganization and FAK phosphorylation. When the cells were 
treated with an EGFR inhibitor, the FAK phosphorylation and cytoskeletal reorganization 
impacts of Egfl7 SiRNA knockdown were abrogated (Wu, Yang et al. 2009). A study by 
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Luo et al. also implicated EGFR signaling in the ability of Egfl7 to impact cancer cell 
migration and invasion (Luo, Xiong et al. 2014). They found that several gastric cancer 
cell lines have high protein expression of Egfl7 and upon downregulation of Egf7 in a 
high expressing cell line, migration was decreased as shown by transwell migration and 
wound closure assays. In addition, overexpression of Egfl7 in a low expressing gastric 
cancer cell line caused an increase in migration of the cells by transwell migration and 
wound closure assays. These effects were abrogated by inhibition of EGFR signaling 
with the EGFR inhibitor Tyrophostin (Luo, Xiong et al. 2014). These studies show that 
treatment of cancer with Egfl7 inhibitors may be a treatment option in patients with solid 
tumors and a risk of invasion and metastasis. In support of using Egfl7 in treatment, a 
study showed that inhibition of VEGF and Egfl7 could decrease the tumor progression 
and survival of mice in a mouse model of advanced non-small cell lung cancer treated 
with anti-VEGF and anti-Egfl7 antibodies (Johnson, Huseni et al. 2013).  
Egfl7 and LOX inhibition 
 When Egfl7 was overexpressed in the keratinocytes of mice, the mice had loose 
skin and Egfl7 colocalized with elastin (Lelievre, Hinek et al. 2008). This indicated that 
Egfl7 could be necessary for the stability or deposition of elastin (Lelievre, Hinek et al. 
2008). Further exploration showed that human fibroblasts cultured with Egfl7 
conditioned media deposited less elastic fibers than human fibroblasts treated with Egfl7 
depleted media and that treatment of MEF (Mouse Embryonic Fibroblasts) with 
recombinant Egfl7 could inhibit LOX activity in MEF supernatant (Lelievre, Hinek et al. 
2008). Since LOX plays an important roll in elastin cross-linking, the group tested the 
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ability of Egfl7 to bind the catalytic domain of LOX in Co-immunoprecipitation 
experiments (Lelievre, Hinek et al. 2008). All isoforms of LOX were found to bind to 
Egfl7 at the catalytic domain (Luo, Xiong et al. 2014). Finally, SiRNA downregulation of 
Egfl7 lead to an increase in LOX activity and more elastin deposition in HUVECs 
(Lelievre, Hinek et al. 2008). Egfl7 can therefore inhibit elastin deposition by binding to 
and inhibiting the catalytic domain of LOX.  
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Rationale, Hypothesis and Specific Aims 
Since Egfl7 was found to inhibit the LOX enzyme, a known promoter of bone marrow 
fibrosis in the Gata-1low mice, we overexpressed Egfl7 in the megakaryocytes of Gata-
1low mice in order to explore whether Egfl7 could inhibit LOX and subsequently, 
myelofibrosis. The research aims of this section are as follows… 
AIM 1. EXPRESSION OF EGFL7 IN THE PF4-EGFL7/GATA-1LOW MOUSE 
MODEL OF MYELOFIBROSIS. 
• mRNA expression of Egfl7 in megakaryocytes of PF4-Egfl7/Gata-1low compared 
to controls (WT and Gata-1low) 
• Protein expression studies of Egfl7 in megakaryocytes of PF4-Egfl7/Gata-1low 
compared to controls (WT and Gata-1low) 
AIM 2.  CHARACTERIZATION OF THE PF4-EGFL7/GATA-1LOW GENETIC 
MOUSE MODEL OF MYELOFIBROSIS. 
• The effect of Egfl7 on megakaryocyte percentage and ploidy as well as peripheral 
blood platelet count in Gata-1low mice. 
• The effect of Egfl7 on spleen size in Gata-1low mice.  
• The effect of Egfl7 on bone marrow fibrosis in Gata-1low mice.   
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Aim 1: EXPRESSION OF EGFL7 IN THE PF4-EGFL7/GATA-1LOW MOUSE 
MODEL OF MYELOFIBROSIS. 
mRNA expression of Egfl7 in the megakaryocytes of PF4-Egfl7/Gata-1low mice 
compared to control mice (WT and Gata-1low). 
To examine the expression of Egfl7 in the megakaryocytes of PF4-Egfl7/Gata-1low mice, 
we measured mRNA level in WT and Gata-1low mice as compared to two founder lines 
of PF4-Egfl7/Gata-1low mice designated as #19 and #2 that were identified based on 
transgene integration into the genome. In order to examine the mRNA expression in WT, 
Gata-1low and the #19 and #2 founder lines of the PF4-Egfl7/Gata-1low mice, we 
isolated RNA from purified megakaryocytes differentiated in vitro, reverse transcribed 
the RNA to cDNA, and performed quantitative PCR using taqman primers that recognize 
sequences that span exon-exon junctions of the Egfl7 gene. Data were normalized to the 
housekeeping gene glyceraldehyde-phosphate-dehydrogenase (GAPDH) mRNA. A two-
fold increase in Egfl7 was detected in the megakaryocytes of #19-PF4-Egfl7/Gata-1low 
megakaryocytes compared to Gata-1low mouse megakaryocytes and a four-fold increase 
in Egfl7 mRNA was detected in the megakaryocytes of #2-PF4/Egfl7/Gata-1low mouse 
megakaryocytes compared to Gata-1low mouse megakaryocytes (Figure 1). No 
significant difference in Egfl7 mRNA expression was noted in Egfl7 mRNA expression 
between WT and Gata-1low mouse megakaryocytes (Figure 1). Analysis of primary, 
non-cultured megakaryocytes was not pursued because of the rarity of this cell type in the 
bone marrow. The analysis of primary, non-cultured megakaryocytes would, therefore, 
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require more mice than we currently have available per data point. This analysis, 
however, should be carried out in the future. 
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Figure 1: Egfl7 mRNA expression analysis in WT, Gata-1low and PF4-Egfl7/Gata-
1low mouse megakaryocytes. 
RNA extracted from primary megakaryocytes differentiated in vitro and purified via a 
BSA density gradient (see methods) was reverse transcribed into cDNA. Taqman primer-
mediated quantitative PCR was done to quantify Egfl7 mRNA expression levels relative 
to GAPDH. Data are averages ± SD. The mice were 10-14 weeks old. The number of 
mice pooled per genotype for this experiment was 1 male and 2 female mice. A one-way 
ANOVA with the bonferonni post-hoc test was used for statistical analysis of this 
experiment. # and ### denote a significance of p<0.05 and p<0.001 in experimental 
samples, respectively compared to the WT samples.  *** denotes a significance of 
p<0.001 in experimental samples compared to Gata-1low samples.  WT= wild type, G= 
Gata-1low, #19= #19-PF4-Egfl7/Gata-1low and #2= #2-PF4-Egfl7/Gata-1low samples. 
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Protein expression studies of Egfl7 in megakaryocytes of PF4-Egfl7/Gata-1low mice 
compared to WT and Gata-1low control mice. 
In order to determine if Egfl7 protein is overexpressed in the PF4-Egfl7/Gata-1low 
mouse megakaryocytes as compared to Gata-1low mouse megakaryocytes, we performed 
western blot analysis, using antibodies against Egfl7 on protein lysate isolated from in 
vitro differentiated primary megakaryocytes. We used protein lysate from HEK cells 
transfected with the Egfl7-pcdna3 plasmid as a positive control and protein lysate from in 
vitro differentiated primary megakaryocytes of Egfl7 null animals (gift of Dr. Calvin 
Kuo’s Lab) as a negative control (Kuhnert, Mancuso et al. 2008). The Egfl7 null animals 
lack exons 5-7 which are the exons that code for the EGF domains and the C-terminal 
half of the EMI domain (Kuhnert, Mancuso et al. 2008). Mouse Egfl7 has 278 amino 
acids and its expected size is 28 kDa (Campagnolo, Leahy et al. 2005). When a His-
tagged Egfl7 plasmid was transfected into HEK cells in previous studies, a 41 kDa 
protein was detected on western blot analysis (Campagnolo, Leahy et al. 2005). The 
higher molecular weight band was noted to be possibly due to the occurrence of 
glycosylation at putative N and O glycosylation sites in the amino acid sequence of the 
protein, leading to the detection of a higher molecular weight band upon western blot 
analysis with an Egfl7 antibody (Fitch, Campagnolo et al. 2004). We detected protein by 
ponseau s stain when the electrophoresed protein lysate from Egfl7-pcdna3 transfected 
HEK cells was transferred to a PVDF membrane (Figure 2a). A ~30 kDa band and a ~50 
kDa band were detected in these cells upon immunoblotting of the membrane with an 
Egfl7 antibody (Figure 2b). We performed western blot analysis on purified 
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megakaryocyte protein lysate which revealed only a band at ~50 kDa as seen in the Egfl7 
transfected HEK cells. This ~50 kDa band was also detected in protein lysate from Egfl7 
knockout megakaryocytes and therefore is not Egfl7 (Figure 3). This result reveals that 
Egfl7 is undetectable in the protein lysate of in vitro differentiated WT, Gata-1low and 
PF4-Egfl7/Gata-1low mouse megakaryocytes by western blot analysis due to a low-level 
expression or the absence of Egfl7 protein in these cells. The Egfl7 mRNA upregulation 
that was seen in the PF4-Egfl7/Gata-1low mouse megakaryocytes as compared to Gata-
1low mouse megakaryocytes did not translate to increased protein expression within the 
cells, as revealed by the above detection method used. Studies have shown that Egfl7 is a 
secreted protein that can be detected in the supernatant of Egfl7 transfected cells (Fitch, 
Campagnolo et al. 2004). We performed western blot analysis on the concentrated 
supernatant of in vitro differentiated megakaryocytes from WT, Gata-1low and PF4-
Egfl7/Gata-1low mice. We used the concentrated supernatant of Egfl7 transfected HEK 
cells as a positive control. A ~30 kDa band was detected in the positive control 
supernatant, but this band was not detected in the WT, Gata-1low or PF4-Egfl7/Gata-
1low megakaryocyte supernatant (Figure 4b). The ponseau s stain of the membrane 
revealed the presence of protein in all of the samples, though the WT sample and the 
positive control sample showed more protein on the membrane than the Gata-1low and 
PF4-Egfl7/Gata-1low samples (Figure 4a). Therefore, we were unable to detect Egfl7 in 
the supernatant of WT, Gata-1low and PF4-Egfl7/Gata-1low megakaryocytes at its 
expected size of ~30 or ~40 kDa. Future experiments should focus on endogenous and 
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secreted Egfl7 in non-cultured megakaryocytes as well as in the serum of the transgenic 
mice. 
 
 
Figure 2: Egfl7 protein expression analysis in HEK 293T cells transfected with 
either Egfl7-pcdna3 plasmid or pcdna3 empty vector. 
Protein lysates from HEK 293T cells transfected with either Egfl7-pcdna3 plasmid or 
pcdna3 empty vector were subjected to western blot analysis using the 18F7 Genentech 
Egfl7 antibody, as described under Methods. The ponceau s stain of the membrane (A) 
and the subsequent detection of Egfl7 expression (B) in transfected cells are shown. Data 
shown are representative of 2 independent experiments. 
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Figure 3: Egfl7 protein expression in WT, Gata-1low and PF4-Egfl7/Gata-1low 
mouse primary megakaryocytes. 
Protein lysate from primary megakaryocytes purified via a BSA density gradient (see 
methods) and differentiated in vitro were subjected to western blot analysis using the 
18F7 antibody. Equal loading was confirmed with an antibody to β-actin. The number of 
mice pooled for megakaryocyte isolation is as follows: n= 1 female for WT, n= 4 females 
pooled for Gata-1low, n= 5 females pooled for #19-PF4-Egfl7/Gata-1low, n= 4 females 
pooled for #2-PF4-Egfl7/Gata-1low samples. These mice were 8-10 weeks old. The 
Egfl7 null mouse pellet was derived from pooling cells from a 17-week-old female 
mouse, 1 10-week-old female mouse, and 1 17-week-old female mouse. 
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Figure 3: Egfl7 protein expression analysis in WT, Gata-1low and PF4-Egfl7/Gata-1low 
mouse primary megakaryocytes. Protein lysates from primary megakaryocytes differentiated in 
vitro were subjected to western blot analysis using the 18F7 Egfl7 antibody. Equal loading of 
protein was confirmed with β5ac7n. 
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Figure 4: Egfl7 protein expression in WT, Gata-1low and PF4-Egfl7/Gata-1low 
mouse primary megakaryocyte supernatant. 
The concentrated supernatant from primary megakaryocytes differentiated in vitro and 
purified via a BSA density gradient (see methods) was subjected to western blot analysis 
using the 18F7 Genentech Egfl7 antibody (A). Equal loading was confirmed with 
ponseau s staining of the membrane (B). The number of mice pooled for megakaryocyte 
isolation was as follows: n= 5 pooled for WT, n= 5 pooled for Gata-1low, n= 5 pooled for 
#19, n= 4 pooled for #2. All mice were 12 weeks old and female. WT= Wild type, G= 
Gata-1low, 19= #19-PF4-Egfl7/Gata-1low, #2= #2-PF4-Egfl7/Gata-1low. 	  
A B 
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Aim 2: CHARACTERIZATION OF THE PF4-EGFL7/GATA-1LOW GENETIC 
MOUSE MODEL OF MYELOFIBROSIS. 
 
The effect of Egfl7 on megakaryocyte percentage and ploidy as well as peripheral 
blood platelet count in Gata-1low mice. 
Upon confirmation of the upregulation of Egfl7 mRNA in transgenic mice, other 
phenotypic analyses were carried out as we continued to decipher Egfl7 protein detection 
issues.  
LOX has been found to boost PDGF-BB-mediated megakaryocyte expansion (Eliades, 
Papadantonakis et al. 2011). Since Egfl7 was found to inhibit LOX activity, we sought to 
assess the impact of Egfl7 upregulation on the percentage of megakaryocytes in the bone 
marrow by comparing the percentage of CD41+ megakaryocytes in the bone marrow by 
flow cytometry in WT, Gata-1low and PF4-Egfl7/Gata-1low mouse bone marrow. We 
also determined the platelet count in the blood using a hemavet analyzer in WT, Gata-
1low and PF4-Egfl7/Gata-1low mice. As previously published (Kuhnert, Mancuso et al. 
2008, Eliades, Papadantonakis et al. 2011), we detected an increase in megakaryocyte 
percentage in the bone marrow of Gata-1low mice compared to WT mice, but there was 
no difference seen in the percentage of megakaryocytes in PF4-Egfl7/Gata-1low 
transgenic bone marrow as compared to the percentage of megakaryocytes in Gata-1low 
bone marrow (Figure 5). In addition, a decrease in platelet count was detected in Gata-
1low mice as compared to WT mice as noted in the literature (Shivdasani, Fujiwara et al. 
1997, Vannucchi, Bianchi et al. 2002). Though there was no significant difference in 
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platelet count seen between PF4-Egfl7/Gata-1low mouse platelet count and Gata-1low 
mouse platelet count, a trend of an increase in platelet count was noted in the #19 founder 
line of the PF4-Egfl7/Gata-1low mice platelet count as compared to Gata-1low mice 
platelet count (Figure 6). We further analyzed the ploidy of the megakaryocytes isolated 
from WT, Gata-1low and PF4-Egfl7/Gata-1low mice in order to assess if there are 
differences in the development of specific ploidy classes by examining the percentage of 
CD41+ cells with 2n, 4n, 8n, 16n, 32n and 64n amounts of DNA by PI staining using 
flow cytometry. As was also reported in the literature (Shivdasani, Fujiwara et al. 1997, 
Vannucchi, Bianchi et al. 2002), we found an increase in the percentage of 2n and 64n 
megakaryocytes in our Gata-1low mouse bone marrow megakaryocytes compared to WT 
mouse bone marrow megakaryocytes (Figure 7). There were no differences detected in 
any of the ploidy classes between PF4-Egfl7/Gata-1low mouse megakaryocytes and 
Gata-1low mouse megakaryocytes (Figure 7), Despite an increase in Egfl7 mRNA 
expression in the PF4-Egfl7/Gata-1low mouse as compared to Gata-1low mice, there was 
no impact detected on megakaryocyte percentage, platelet count or megakaryocyte 
ploidy. More studies are needed to increase the samples size of our data since these 
conclusions are based on our analyses of small numbers of available mice. 
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Figure 5: Megakaryocyte percentage in the bone marrow of male WT, Gata-1low 
and PF4-Egfl7/Gata-1low mice at 30 and 40 weeks of age. 
Bone marrow cells from WT, Gata-1low and PF4-Egfl7/Gata-1low male mice at 30 
weeks (A) and 40 weeks (B) were stained for the lineage specific markers B220 (stains B 
cells), Ter119 (stains erythrocytes), Gr-1 (stains granulocytes) and CD3 (stains T cells) as 
well as the megakaryocyte marker CD41. The percentage of lineage specific marker 
negative CD41+ cells was quantified by flow cytometry. WT= Wild type, G= Gata-1low, 
19= #19-PF4-Egfl7/Gata-1low, #2= #2-PF4-Egfl7/Gata-1low. A one-way ANOVA with 
the bonferonni post-hoc test was used for statistical analysis of this experiment. ## and 
### denotes a significance of p<0.01 and p<0.001 in experimental samples, respectively 
compared to the WT samples.   
## 
### 
A 
B 
WT (n=4) G (n=5) #19 (n=6) #2 (n=2)
0.0
0.1
0.2
0.3
0.4
30 Weeks
%
 L
in
- C
D
41
+
WT (n=2) G (n=5) #19 (n=4) #2 (n=3)
0.0
0.1
0.2
0.3
       40 Weeks
%
 L
in
- C
D4
1+
30 eeks 
40 Weeks 
T  
(n=4) 
G 
(n=5) 
#19 
(n=6) 
#2 
(n=2) 
WT  
(n=1) 
G 
(n=2) 
#19 
(n=4) 
#2 
(n=3) 
%
Li
n-
 C
D
41
+ 
%
Li
n-
 C
D
41
+ 
		
55 
 
40 Weeks
WT (n=1) G (n=3) #19 (n=5) #2 (n=3)
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
K
/µ
l
WT G #19 #2 
40 Weeks 
K
/µ
l 
10 weeks
WT (n=6) G (n=8) #19 (n=10) #2 (n=5)
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
K
/µ
l
T G #19 #2 
10 Weeks 
K
/µ
l 
### ### ### 
30 weeks
WT (n=3) G (n=11) #19 (n=11) #2 (n=4)
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
K
/µ
l
WT G #19 #2 
30 Weeks 
K
/µ
l 
### ### ### 
20 Weeks
WT (n=9) G (n=21) #19 (n=17) #2 (n=3)
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
K
/µ
l
WT G #19 #2 
20 Weeks 
K
/µ
l 
### ### ### 
A 
B 
C 
D 
		
56 
Figure 6: Platelet Count in the blood of male WT, Gata-1low and PF4-Egfl7/Gata-
1low mice at 10, 20, 30 and 40 weeks of age.  
Platelet count was measured using a hemavet analyzer in blood isolated via retroorbital 
bleeding from WT, Gata1-low and PF4-Egfl7/Gata-1low mice at 10 (A), 20 (B), 30 (C) 
and 40 (D) weeks of age. A one-way ANOVA with the bonferonni post-hoc test was used 
for statistical analysis of this experiment. ### denotes a significance of p<0.001 in 
experimental samples compared to the WT samples. WT= wild type, G= Gata-1low, 
#19= #19-PF4-Egfl7/Gata-1low and #2= #2-PF4-Egfl7/Gata-1low samples. 
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Figure 7: Megakaryocyte ploidy in the bone marrow of male WT, Gata-1low and 
PF4-Egfl7/Gata-1low mice at 20, 30 and 40 weeks of age. 
Bone marrow cells from WT, Gata-1low and PF4-Egfl7/Gata-1low male mice at 20 
weeks (A), 30 weeks (B) and 40 weeks (C) were stained for lineage specific markers 
B220 (stains B cells), Ter119 (stains erythrocytes), Gr-1 (stains granulocytes) and CD3 
(stains T cells) as well as the megakaryocyte marker CD41. The percentage of lineage 
negative CD41+ cells containing 2n, 4n, 8n, 16n, 32n and 64n amounts of DNA were 
quantified by flow cytometry using PI DNA staining. #19= #19-PF4-Egfl7/Gata-1low 
mice and #2= #2-PF4-Egfl7/Gata-1low mice. The number of mice represented is as 
follows: at 10 weeks n=1 for WT, n=2 for Gata-1low, n=2 for #19, n=1 for #2, at 30 
weeks n=1 for WT, n=2 for Gata-1low, n=5 for #19, n=2 for #2, at 40 weeks n=0 for WT, 
n=2 for Gata-1low, n=2 for #19, n=3 for #2. #19= #19-PF4-Egfl7/Gata-1low and #2= #2-
PF4-Egfl7/Gata-1low. A statistical analysis was not performed for this experiment due to 
the low numbers of experimental animals used.  
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The effect of Egfl7 on spleen size in Gata-1low mice. 
 
In PMF, progenitor cells are mobilized from the bone marrow to the spleen and liver 
where extramedullary hematopoiesis begins to take place (Le Bousse-Kerdiles 2012). 
This increase in hematopoiesis in the spleen causes the hepatosplenomegaly seen in PMF 
patients (Le Bousse-Kerdiles 2012). The cause of the splenomegaly that is present in the 
Gata-1low mice has not been clearly identified, but is likely directly related to the 
increase in megakaryocytes present in the spleen as well as splenic fibrosis (Vannucchi, 
Bianchi et al. 2002). Since LOX inhibits the bone marrow fibrosis in the Gata-1low mice, 
we examined whether upregulation of Egfl7 in the megakaryocytes of the Gata-1low 
mice could decrease spleen size due to a decrease in splenic fibrosis. As published in 
previous studies (Shivdasani, Fujiwara et al. 1997, Vannucchi, Bianchi et al. 2002), we 
found an increase in the spleen weight of the Gata-1low mice compared to WT mice as 
previously published (Vannucchi, Bianchi et al. 2002), but we did not detect a significant 
difference in spleen size between PF4-Egfl7/Gata-1low mice and Gata-1low mice at 10 
weeks, 20 weeks, 30 weeks or 40 weeks (Figure 8). Therefore, upregulation of Egfl7 
mRNA in the Gata-1low megakaryocytes does not ameliorate the spleen size increase 
that occurs in the Gata-1low mice. 
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Figure 8: Spleen size in male WT, Gata-1low and PF4-Egfl7/Gata-1low male mice at 
10, 20, 30 and 40 weeks of age. 
Spleen weight and body weight were measured immediately after euthanization with 
isofluorane of WT, Gata-1low and PF4-Egfl7/Gata-1low mice and the ratio of spleen 
weight to body weight was calculated at 10 weeks (A), 20 weeks (B), 30 weeks (C) and 
40 weeks (D). WT= Wild type, G= Gata-1low, 19= #19-PF4-Egfl7/Gata-1low, 2= #2-
PF4-Egfl7/Gata-1low. A one-way ANOVA with the bonferonni post-hoc test was used 
for statistical analysis of this experiment. ## and ### denotes a significance of p<0.01 
and p<0.001 in experimental samples, respectively compared to the WT samples.   
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The effect of Egfl7 on bone marrow fibrosis in Gata-1low mice. 
Lysyl Oxidase, an enzyme involved in collagen cross-linking, promotes bone marrow 
fibrosis in the Gata-1low mice (Eliades, Papadantonakis et al. 2011). Lelievre et al. 
reported that Egfl7 binds LOX enzymes at their catalytic domains and inhibits the 
enzyme, causing a decrease in the ability of the LOX to catalyze the production of elastin 
from tropoelastin monomers (Lelievre, Hinek et al. 2008). We hypothesized that 
overexpressing Egfl7 in the Gata-1low mice would inhibit LOX and cause a decrease in 
fibrosis in the PF4-Egfl7/Gata-1low mice compared to Gata-1low mice. Three methods 
of quantitation were utilized in order to measure the amount of reticulin fibers in WT, 
Gata-1low and PF4-Egfl7/Gata-1low mice. These methods included (1) measuring the 
integrated density of binary images of reticulin stained femur sections at a set threshold, 
(2) measuring the integrated density of binary images of reticulin stained femur sections 
at a threshold that would decrease the background signal of individual slides and (3) 
measuring the reticulin fibrosis in reticulin stained femur sections using semi-quantitative 
pathologic criteria. For the semi-quantitative pathologic criteria, reticulin stained femur 
sections that received a grade of 1 contained no detectable level of fibrosis. A grade of 
1.5 was reserved for section with reticulin fibers that were barely noticeable. A grade of 2 
was assigned to sections, which displayed light reticulin fibers near the endosteum. A 
grade of 3 was given to sections that showed dark reticulin staining near the endosteum. 
A grade of 4 was given to sections with a high degree of reticulin fibers throughout the 
marrow space. A 70-week old JAK2V617F transgenic mouse with extensive reticulin 
fibrosis was used as a positive control. Evidently, this type of grading depends on 
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persistent, uniform evaluation of what is perceived as low or high degree of fibers in 
different sections. Since I set up this scale for this line of experiments, I did my best to be 
consistent in what I evaluate as levels 1-4 in different sections. All methods of 
quantitation detected an increase in reticulin fibrosis between WT and JAK2V617F 
transgenic mice (Figure 9, 10). A difference in reticulin fibrosis between WT and Gata-
1low mice at 30 weeks was only detected when the threshold was set to minimize 
background signal, as well as when the semi-quantitative pathologic criteria was used 
(Figure 9, 10). With the limited number of mice analyzed thus far (at times, only 3 mice 
available per genotype), we did not detect a significant difference in bone marrow 
fibrosis between Gata-1low and PF4-Egfl7/Gata-1low mice using any of the methods of 
quantitation (Figure 9, 10).  If these results are repeatable in the future upon analysis of a 
greater number of mice, and perhaps with other imaging modalities, we would conclude 
that mRNA upregulation of Egfl7 in the Gata-1low mouse megakaryocytes is unable to 
ameliorate the bone marrow fibrosis that is present in the Gata-1low mice at 30 weeks of 
age. 
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Figure 9: Bone marrow fibrosis quantitation using semi-quantitative pathologic 
criteria. 
Femur sections from 30-week old male WT, Gata-1low, PF4-Egfl7/Gata-1low and a 70-
week old JAK2V617F mouse were silver stained for reticulin fibers and blinded. Pictures 
from the mid-diaphysis were acquired and a panoramic view of the mid-diaphysis was 
created in photoshop (A) and graded using semi-quantitative pathologic criteria (B). 
Three panoramic images were acquired and graded at the mid-diaphysis per femur 
section and three femur sections were analyzed per animal. WT= Wild type, G= Gata-
1low, 19= #19-PF4-Egfl7/Gata-1low, #2= #2-PF4-Egfl7/Gata-1low. Yellow arrows point 
to reticulin fibers. A one-way ANOVA with the bonferonni post-hoc test was used for 
statistical analysis of this experiment. # and ## denotes a significance of p<0.05 and 
p<0.01 in experimental samples, respectively compared to the WT samples.   
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Figure 10: Bone marrow fibrosis quantitation by Image J analysis in WT, Gata-
1low and PF4-Egfl7/Gata-1low male mice.  
Femur sections from 30-40 week old WT, Gata-1low, PF4-Egfl7/Gata-1low mice and a 
70-week old JAK2V617F mouse were silver stained and blinded. Pictures from the mid-
diaphysis were acquired. Integrated Density was obtained by Image J analysis using 
binary images at a threshold of 150 (A) or at varying thresholds that minimized 
background interference (B). Three panoramic images were acquired and graded at the 
mid-diaphysis per femur section and three femur sections were analyzed per animal. One 
20x hpf was quantified per panoramic image. WT= Wild type, G= Gata-1low, 19= #19-
PF4-Egfl7/Gata-1low, #2= #2-PF4-Egfl7/Gata-1low. A one-way ANOVA with the 
bonferonni post-hoc test was used for statistical analysis of this experiment. # and ## 
denotes a significance of p<0.05 and p<0.01 in experimental samples, respectively 
compared to the WT samples. 
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Discussion & Conclusion 
The studies in chapter III were done in order to evaluate the ability of Egfl7 to inhibit 
LOX and reduce the myelofibrotic phenotype of the Gata-1low mice (Ravid, Beeler et al. 
1991, Shivdasani, Fujiwara et al. 1997). To determine if this is the case, we created the 
PF4-Egfl7/Gata-1low transgenic mice, which contain the megakaryocyte and platelet 
specific PF4 promoter driving expression of Egfl7 for the goal of overexpressing Egfl7 in 
the megakaryocytes of the Gata-1low mice. The mouse was created in the transgenic core 
of BU in a collaboration between Greg Martin and Dr. Shinobu Matsuura. Dr. Rongjuan 
Mi and Dr. Shinobu Matsuura analyzed and confirmed transgene integration in two 
founder lines (#19 and #2) by qPCR analysis. Next, Dr. Rongjuan Mi performed a 
preliminary analysis of mRNA expression of Egfl7 in the megakaryocytes of the 
homozygotes of the F2 generation in the PF4-Egfl7/Gata-1low founders. The studies in 
this thesis were done in collaboration with Dr. Shinobu Matsuura. The studies began with 
confirming the mRNA overexpression of Egfl7 in the megakaryocytes of the PF4-
Egfl7/Gata-1low mice as compared to Gata-1low mice (Aim 1). We also explored 
whether Egfl7 protein is overexpressed in the PF4-Egfl7/Gata-1low transgenic mice 
compared to Gata-1low mice (Aim 1) as well as analyzed the myelofibrotic phenotype of 
the PF4-Egfl7/Gata-1low mice (Aim 2).  
Aim One: 
Upon analyzing Egfl7 expression in megakaryocytes of our mice, we found a 2-fold 
increase in Egfl7 mRNA expression in the #19 line of the PF4-Egfl7/Gata-1low 
transgenic mice and a 2.5-fold increase in Egfl7 mRNA expression in the #2 line of the 
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PF4-Egfl7/Gata-1low transgenic mice compared to Gata-1low mice. We did not detect an 
increase in Egfl7 protein expression in large, high ploidy (BSA density gradient-purified) 
megakaryocyte cell lysate or supernatant of PF4-Egfl7/Gata-1low mice compared to 
Gata-1low mice. This could be due to a lack of or low level of Egfl7 protein expression in 
the megakaryocytes from the WT, Gata-1low and PF4-Egfl7/Gata-1low mice. Many 
studies have shown that protein expression may not correlate with mRNA expression due 
to inhibition of translation of mRNAs or decreased stability of  proteins (Maier, Guell et 
al. 2009). This means that despite the increase in mRNA expression seen in the PF4-
Egfl7/Gata-1low mice, there is a possibility that the mRNA could not be translated or that 
the protein could be degraded as soon as it is translated. Future studies might include 
analyzing non-cultured megakaryocytes as in vitro culturing may impact our ability to 
detect Egfl7 protein expression in the megakaryocytes if mRNA regulation or protein 
stability has been affected by in vitro conditions. In addition, Egfl7 contains an EMI-like 
domain, which is known to mediate protein binding to the ECM (Nichol and Stuhlmann 
2012). If Egfl7 is secreted from the megakaryocytes of our PF4-Egfl7/Gata-1low 
transgenic mice as soon as it is translated and then immediately binds to the ECM on the 
culture dish, then it would be very difficult to detect protein expression in vitro in the 
supernatant of the megakaryocytes and in the megakaryocytes themselves. Further 
studies examining the ECM as well as cell lysates of megakaryocytes treated with protein 
degradation inhibitor would help us to conclude if Egfl7 is upregulated in the PF4-
Egfl7/Gata-1low mouse megakaryocytes as compared to Gata-1low mice. In addition, 
studies in Egfl7 protein expression of non-cultured megakaryocytes would also be 
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beneficial in order to remove the impact of in vitro culture conditions on protein 
expression.  
Aim Two: 
 We did not detect a difference in megakaryocyte percentage in the bone marrow, 
megakaryocyte ploidy, platelet count, bone marrow fibrosis or spleen size in our PF4-
Egfl7/Gata-1low mice as compared to the Gata-1low mice with the number of mice 
available for analysis. This is stated with the following stipulations: platelet count for 
some age groups was carried out with 1-3 mice (see Figure 6). There might be a need for 
analysis of a greater number of mice to see small differences in the transgenic animals 
compared to Gata-1low control animals.  As seen in previous publications, the Gata-1low 
mice portrayed an increase in 2n megakaryocyte percentage of CD41+ megakaryocytes 
in the bone marrow, a decrease in platelet count, an increase in bone marrow fibrosis and 
an increase in spleen size as compared to WT mice (Vyas, Ault et al. 1999, Vannucchi, 
Bianchi et al. 2002). Since we have not been able to detect an upregulation of functional 
Egfl7 in the megakaryocytes of the PF4-Egfl7/Gata-1low mice, it is likely that there is 
either no or a very small increase in Egfl7 protein in the megakaryocytes of the 
transgenic mice as compared to Gata-1low mice.  Without a sufficient amount of 
functional Egfl7, the PF4-Egfl7/Gata-1low mouse phenotype would be comparable to 
what is seen in the Gata-1low mice. Therefore the lack of differences in phenotype 
between the PF4-Egfl7/Gata-1low mice and Gata-1low mice could be due to the lack of 
detectable Egfl7 protein expression in our mice.  
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 If Egfl7 is overexpressed at a level that is sufficient for the inhibition of LOX 
activity in our transgenic mice, there could be several reasons that we may not detect a 
phenotypic difference between the PF4-Egfl7/Gata-1low transgenic mice and Gata-1low 
mice. As the specific binding site on Egfl7 that binds LOX has not been studied, there is 
a possibility that the Egfl7 produced in the megakaryocytes of the Gata-1low mice 
contain differences in modifications that may influence its ability to completely bind and 
inhibit LOX. In addition, the ability of Egfl7 to impact collagen cross-linking has not 
been determined. A role for Egfl7 in elastin matrix organization in Egfl7 treated 
fibroblast culture has been recognized, but further preliminary studies failed to show an 
affect of Egfl7 on collagen matrix reorganization in Egfl7 treated fibroblast culture 
(Lelievre, Hinek et al. 2008). If the impact that Egfl7 has on LOX does not influence 
collagen cross-linking, then we would not be able to ameliorate the myelofibrotic 
phenotype of the Gata-1low mice by inhibiting LOX by overexpression of Egfl7 in the 
bone marrow of the Gata-1low mice. Also, the ability of Egfl7 to inhibit LOX and 
decrease PDGF mediated megakaryocyte expansion has not been assessed. If Egfl7 does 
not influence megakaryocyte expansion (through LOX or other mechanisms), then we 
would not be able to detect differences in this parameter in our in vivo studies.  
 These studies have a limitation of a small sample size in several experiments. The 
percentage and ploidy of megakaryocytes in the bone marrow was assessed in a 
maximum of 6 animals per genotype. Also, in some genotypes, only 3 animals were 
analyzed for peripheral blood platelet count. At 40 weeks, only 3 animals were used to 
measure spleen size in Gata-1low and #2 animals. In addition, for fibrosis studies, only 4 
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and 3  #19 and #2 transgenic animals were analyzed, respectively. Therefore, more 
animals are needed to finalize these experiments and to come to a conclusion on if PF4-
Egfl7/Gata-1low transgenic animals contain significant differences in megakaryocyte 
ploidy and percentage in the bone marrow, spleen size, platelet count and bone marrow 
fibrosis as compared to Gata-1low mice. It should be noted that for every parameter 
tested, differences between WT animals and Gata-1low animals persisted as previously 
published (Vannucchi, Bianchi et al. 2004) despite low animal numbers. This shows that 
decreasing the level of Gata-1 has a large influence on the phenotype of WT mice, which 
is much larger than the impact that upregulation of Egfl7 mRNA has on the phenotype of 
Gata-1low mice.  
 There are several limitations evident in the quantitation of bone marrow fibrosis 
using the pathologic criteria and Image J analysis of reticulin fibers in femur sections 
from experimental samples. For the pathologic analysis, only one observer analyzed the 
blinded slides. Though the bias of the observer was removed due to blinding of the slides, 
it is unknown if other observers would have come to the same conclusion. Therefore, 
additional observers are necessary to confirm these results. Second, for both the Image J 
and pathologic criteria analyses, three panoramic views of the mid-diaphysis were 
analyzed per femur section and three femur sections were analyzed per femur. This 
means that other areas of the bone were not evaluated for fibrosis. For the pathologic 
criteria, this amounted to between 54 and 117 images analyzed per animal and for the 
Image J analysis this amounted to nine images per animal. Further studies are needed to 
analyze other areas of the femur in order to examine if there are differences in fibrosis in 
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those areas due to Egfl7 mRNA upregulation in mice of the Gata-1low background. 
Third, there was a high signal to noise ratio for the Image J analysis during quantitation 
of reticulin fibrosis. This made using a fixed threshold impossible because the use of this 
method resulted in equal values between WT and Gata-1low samples. We decided to 
quantify the reticulin fibers in the femur sections manually by subjectively choosing a 
threshold for each image that would minimize background. This subjective decision may 
be different between individuals and further analysis by other individuals is needed in 
order to confirm the result. 
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CHAPTER IV: SEX DIFFERENCES IN OSTEOSCLEROSIS 
Background 
Bone Structure and Function 
Bone is a mineralized matrix that is important for many activities such as movement, the 
protection of tissues from injury and the storage of crystalline hydroxyapatite (calcium 
and phosphate) (Compston 2002, Florencio-Silva, Sasso et al. 2015). There is an 
inorganic portion, which consists of 99% hydroxyapatite and an organic portion, which 
consists of 90% collagen I and 10% non-collagen (osteocalcin and proteoglycan) 
(Compston 2002, Florencio-Silva, Sasso et al. 2015). The two components of bone 
architecture are the cortical bone and the trabecular bone (Florencio-Silva, Sasso et al. 
2015). The cortical bone is the bone surrounding the bone marrow that is dense and solid 
(Florencio-Silva, Sasso et al. 2015). It has a periosteal side on the outermost layer of the 
bone and an endosteal side on the innermost side of the bone (Florencio-Silva, Sasso et 
al. 2015).  The trabecular bone is located within the marrow space (Florencio-Silva, 
Sasso et al. 2015). It is less dense and honey combed shaped bone with a larger surface 
area and higher metabolic rate (Florencio-Silva, Sasso et al. 2015).  
Bone Remodeling 
Bone remodeling (the process of old bone replacement by new bone) starts with the 
resorption of bone by osteoclasts and finishes with the formation of bone by osteoblasts 
(Compston 2002, Florencio-Silva, Sasso et al. 2015).  Osteoblasts are cuboidal cells that 
are located on the surface of bone and derived from mesenchymal stem cells (Compston 
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2002, Florencio-Silva, Sasso et al. 2015). They participate in forming bone because they 
secrete bone matrix (collagen I, non-collagen proteins and proteoglycans) and matrix 
vesicles (calcium and phosphorous) that rupture upon supersaturation with 
hydroxyapatite crystals. The mixture of hydroxyapatite crystals and bone matrix confers 
rigidity to the newly formed bone (Kini and Nandeesh 2012, Florencio-Silva, Sasso et al. 
2015). Osteoblasts also have the ability to secrete proteins that affect osteoclast activity 
such as Receptor Activator of Nuclear Kappa-B Ligand (RANKL) and Osteoprotegerin 
(OPG) (Florencio-Silva, Sasso et al. 2015). Osteoclasts are larger, multinucleated cells 
that differentiate from monocytes and have the ability to resorb bone (Florencio-Silva, 
Sasso et al. 2015). Osteoclast precursors express the RANK receptor on their plasma 
membrane, which bind RANKL released from osteoblasts and stromal cells. The binding 
of RANKL to osteoclast precursors promotes their differentiation into fully differentiated 
osteoclasts (Florencio-Silva, Sasso et al. 2015). OPG secreted from osteoblasts and 
fibroblasts can bind RANKL and act as a decoy so that RANKL can no longer bind to the 
RANK receptor on osteoclast precursors (Florencio-Silva, Sasso et al. 2015). OPG 
secretion thus leads to decreased osteoclastogenesis, less osteoclasts and a resultant 
increase in bone formation due to less bone resorption (Florencio-Silva, Sasso et al. 
2015).  
MPN and Osteosclerosis 
Osteosclerosis (the increase in trabecular bone within the bone marrow) is seen in 
post-PV fibrosis and post-ET fibrosis as well as PMF (Teman, Wilson et al. 2010). 
Several studies have examined the osteosclerosis seen in myelofibrosis and shown that 
		
76 
bone marrow biopsies of patients with MPN-related myelofibrosis have more trabecular 
bone than healthy control bone biopsies (Poulsen, Melsen et al. 1998, Schmidt, Blanchet 
et al. 2007, Teman, Wilson et al. 2010). Mellibovsky et al. assessed the bone marrow of 
five PMF patients through histomorphometry and found that there was a positive balance 
of bone formation and a decrease in osteoclast number and activity in the PMF patients 
(Mellibovsky, Marinoso et al. 2004). Schmidt et al. performed bone histomorphometry 
on bone marrow biopsies from 12 patients and noted an increase in bone formation rate, a 
decrease in osteoclast number and activity and a greater recruitment of osteoblasts 
(Schmidt, Blanchet et al. 2007).  
Patient studies support the role that OPG plays in PMF in that PMF patients have 
increased OPG in their blood plasma (Wang, Hemavathy et al. 2004). In addition, Bock 
et al. attained bone marrow biopsies from PMF patients with varying degrees of bone 
marrow fibrosis (Bock, Loch et al. 2005). Upon isolation and reverse transcription of 
RNA and subsequent qPCR using OPG and RANKL primers, it was found that patients 
samples determined to have more advanced fibrosis and osteosclerosis had a 71-fold 
expression level of OPG while there was no difference in RANKL expression in PMF 
patients compared to non-neoplastic and less advanced stage disease (Bock, Loch et al. 
2005). Upon IHC, it was found that the OPG in the advanced stage disease was localized 
mainly to the endothelial cells and minimally to fibroblasts and megakaryocytes (Bock, 
Loch et al. 2005). RANKL showed no significant localization in the tissue biopsy 
sections (Bock, Loch et al. 2005). This study showed that osteoclasts and osteoblasts may 
play a role in the osteosclerosis seen in PMF by promoting a decrease in bone resorption.  
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Several studies have examined the role that megakaryocytes play in the 
osteosclerosis seen in PMF using animal models. Meijome et al. used Gata-1low mice 
which display extensive osteosclerosis and measured OPG levels in the serum using an 
ELISA (Meijome, Hooker et al. 2015). They found an increase in OPG in the Gata-1low 
mice which correlated with the number of megakaryocytes in the bone marrow 
(Meijome, Hooker et al. 2015). Another study showed that osteoblasts co-cultured with 
megakaryocytes exhibit more OPG expression and less RANKL expression, which 
indicated that megakaryocytes can alter osteoblastic expression of proteins that modulate 
bone resorption by osteoclasts (Bord, Frith et al. 2005). Analysis of Gata-1low mice has 
not shown a difference in the number osteoclasts as compared to WT, though osteoblast 
number was increased (Kacena, Shivdasani et al. 2004). When Gata-1low 
megakaryocytes were co-cultured with osteoblasts, an increased osteoblast proliferation 
was seen (Kacena, Shivdasani et al. 2004). Therefore megakaryocytes may play a role in 
the progression of osteosclerosis by stimulating osteoblasts to increase bone formation.  
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Rational, Hypothesis & Specific Aims 
We examined the progression of osteosclerosis in the Gata-1low mice and found that the 
female Gata-1low mice displayed an increase in the progression to osteosclerosis as 
compared to male Gata-1low mice. Our research aims were as follows: 
AIM 1. TO CHARACTERIZE SEX DIFFERENCES IN OSTEOSCLEROSIS IN MALE 
AND FEMALE GATA-1LOW MICE. 
• Comparison of radiodensity in WT and Gata-1low male and female femurs. 
• Comparison of trabecular bone in WT and Gata-1low male and female femurs. 
AIM 2. TO EXAMINE GATA-1 EXPRESSION IN MEGAKARYOCYTES, 
MEGAKARYOCYTE PERCENTAGE WITHIN THE BONE MARROW AND 
OSTEOCLAST NUMBER IN THE BONE MARROW OF GATA-1LOW MALE 
VERSUS FEMALE MIC 
• Comparison of Gata-1 mRNA expression in megakaryocytes derived from Gata-
1low male and female mice. 
• Megakaryocyte number in male and female Gata-1low mice. 
• Osteoclast number in male and female Gata-1low mice. 
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Results 
AIM 1. TO CHARACTERIZE SEX DIFFERENCES IN OSTEOSCLEROSIS IN MALE 
AND FEMALE GATA-1LOW MICE. 
Comparison of radiodensity in WT and Gata-1low male and female femurs. 
An increase in trabecular bone has been detected in Gata-1low male mice as compared to 
WT male mice at 5 and 9 months of age using µCT and bone histomorphometry (Kacena, 
Shivdasani et al. 2004). In order to evaluate bone differences between Gata-1low male 
and female mice, we performed X-radiography on male and female WT and Gata-1low 
mouse femurs at 2.5, 5 and 8 months of age. The medullary space of the Gata-1low male 
and female mouse femurs were radiolucent at 2.5 months of age, except for an area of 
radiodensity at the proximal and distal ends of the femur in the region where trabecular 
bone is normally located (Figure 11b). The radiodensity within the Gata-1low female 
mice progressed into the femur shaft towards the mid-diaphysis at 5 months and 
completely filled the femur shaft at 8 months (Figure 11c,d). At 5 months, the Gata-1low 
male mice did not show a progression of radiodensity within the femur shaft, but at 8 
months, one out of three femurs showed a progression towards a higher radiodensity 
within the diaphysis of the femur similar to what was seen in the Gata-1low female mice 
(Figure 11c,d). An area of radiolucency within the mid-diaphysis of the Gata-1low 
female mice at 8 months was absent (Figure 11d). At 12 months, the WT male and 
female mice did not show a progression of radiodensity into the femur shaft (Figure 
11a). Therefore, female Gata-1low mice show a higher progression of radiodensity 
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within the femur from 2.5 months to 8 months of age, as compared to Gata-1low male 
mice, presumably due to increased trabecular bone formation. 
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Figure 11: Radiodensity in WT and Gata-1low male and female mouse femurs. 
Paraformaldehyde fixed femurs from male and female Gata-1low mice were subjected to 
X-radiography at 2.5 months (B), 5 months (C) and 8 months (D). Paraformaldehyde 
fixed femurs from WT male and female mice were subjected to X-radiography at 12 
months of age (A). Red circles indicate areas of radiolucency. 
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Comparison of trabecular bone in WT and Gata-1low male and female femurs. 
In order to confirm the increase in trabecular bone volume that is seen in the Gata-1low 
female mice as compared to Gata-1low male mice, we stained cross-sections of the mid-
diaphysis of the femur with H&E stain and visualized the extent of trabecular bone 
infiltration into the marrow cavity in the mid-diaphysis at 2.5, 5 and 8 months of age in 
Gata-1low male and female mice. Our results mirrored the X-radiography results in that 
we did not see an increase in trabecular bone within the marrow cavity at 2.5 months in 
Gata-1low male or female mice (Figure 12b). At five months, Gata-1low female mice 
displayed an increase in trabecular bone formation within the marrow cavity that was not 
seen in Gata-1low male mice (Figure 12c). At 8 months, all of the Gata-1low females 
showed complete trabecular bone infiltration within the marrow cavity while only 1 out 
of 3 of the Gata-1low male mice showed a partial infiltration of trabecular bone within 
the marrow cavity (Figure 12d). WT male and female mice at 8 months did not show any 
infiltration of trabecular bone within the marrow cavity (Figure 12a). This confirms that 
Gata-1low female mice have an increased progression to trabecular bone infiltration 
within the marrow cavity as compared to Gata-1low male mice. 
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Figure 12: Trabecular Bone infiltration in WT and Gata-1low male and female 
mouse femurs.  
Parformaldehyde fixed femurs were decalcified, paraffin-embedded, sectioned and placed 
on slides. Femur sections from male and female WT mice were subjected to H&E 
staining at 8 months of age (A). Femur sections from Gata-1low male and female mice 
were subjected to H&E staining at 2.5 months (B), 5 months (C) and 8 months of age 
(D). Black arrows indicate areas of trabecular bone infiltration. 	  
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AIM 2. TO EXAMINE GATA-1 EXPRESSION IN MEGAKARYOCYTES, 
MEGAKARYOCYTE PERCENTAGE WITHIN THE BONE MARROW AND 
OSTEOCLAST NUMBER IN THE BONE MARROW OF GATA-1LOW MALE 
VERSUS FEMALE MICE. 
 
Comparison of Gata-1 mRNA expression in megakaryocytes derived from Gata-
1low male and female mice. 
A decrease in Gata-1 levels in the Gata-1low mice results in an increase in bone marrow 
megakaryocyte number, which release growth factors such as PDGF and TGFβ 
(Vannucchi, Bianchi et al. 2002). This high level of growth factors is implicated in 
causing osteosclerosis and bone marrow fibrosis (Ciurea, Merchant et al. 2007). In order 
to determine if megakaryocytes in female Gata-1low mice express less Gata-1, thus 
triggering an even higher level of cytokines and more trabecular bone volume, we 
analyzed the Gata-1 mRNA expression in in vitro differentiated megakaryocytes that 
were isolated from Gata-1low male and female mice and purified using a BSA density 
gradient. We found that Gata-1 expression was similarly low in Gata-1 male and Gata-
1low female megakaryocytes as compared to WT male control megakaryocytes (Figure 
13). Further measurements in non-cultured megakaryocytes are needed in order to 
examine whether a decrease in Gata-1 expression level is associated with the increase in 
osteosclerosis seen in Gata-1low female mice. 
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Figure 13: Gata-1 expression in male and female WT and Gata-1low mice at 2.5 
months of age. 
RNA extracted from primary megakaryocytes differentiated in vitro and purified via a 
BSA gradient (see methods), was reverse transcribed into cDNA. Taqman primer-
mediated quantitative PCR was done to quantify Gata-1 mRNA expression levels relative 
to GAPDH in WT male and Gata-1low male and female in vitro differentiated and BSA 
density gradient purified megakaryocytes. Data are averages ± SD. The number of mice 
pooled for megakaryocyte isolation is as follows: n= 3 pooled for WT male mice, n= 3 
pooled for Gata-1low male mice, n= 3 pooled for Gata-1low female mice. A one-way 
ANOVA with the bonferonni post-hoc test was used for statistical analysis of this 
experiment. *** denotes a significance of p<0.001 in experimental samples, compared to 
the WT male sample.   
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Megakaryocyte number in the bone marrow of male and female Gata-1low mice. 
Gata-1low mice have an increased number of megakaryocytes, which leads to a greater 
expression of growth factors in the bone marrow (Vannucchi, Bianchi et al. 2002). We 
sought to find out whether megakaryocyte number is increased in Gata-1low female mice 
as compared to Gata-1low male mice, which could be leading to increased amounts of 
growth factors and, thus, more bone formation within the medullary cavity of the Gata-
1low female mice. As previously published (Vannucchi, Bianchi et al. 2002), we detected 
an increase in megakaryocyte number in Gata-1low mice as compared to WT mice at 2.5 
months and 5 months of age (Figure 14a,b). We did not discover a difference in 
megakaryocyte number in the bone marrow at 2.5 months of age between male and 
female Gata-1low mice (Figure 14a). At 5 months of age, we noticed a trend towards 
lower megakaryocytes in the Gata-1low female mice (Figure 14b). This shows that an 
increase in megakaryocyte number is not the reason for augmented bone formation seen 
in Gata-1low female mice. 
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Figure 14: Megakaryocyte number in the femur of male and female WT and female 
Gata-1low mice at 2.5 months and 5 months of age. 
Paraformaldehyde fixed femur sections were decalcified, processed, paraffin-embedded, 
sectioned and placed on slides. Sections were stained with H&E stain, blinded, pictures 
were acquired and megakaryocytes were counted in male and female WT and Gata-1low 
femur sections at 2.5 months (A) and 5 months (B). Five areas of each femur section 
were counted and three femur sections were analyzed per mouse. Each hpf is 20x 
magnification. The following number of animals were used in this experiment: At 10 
weeks, n=2 for WT male, n=3 for WT female, n=3 for Gata-1low male and n=3 for Gata-
1low female. At 20 weeks: n=3 for WT male, n=3 for WT female, n=3 for Gata-1low 
male and n=2 for Gata-1low female. A two-way ANOVA with the bonferonni post-hoc 
test was used for statistical analysis of this experiment. * and ** denotes a significance of 
p<0.05 and p<0.01 in experimental samples, respectively compared to the WT samples of 
the same gender.    
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Osteoclast number in male and female Gata-1low mice 
Studies have shown that osteoclast number per tissue area is increased in the Gata-1low 
mice as compared to WT mice (Garimella, Kacena et al. 2007, Meijome, Hooker et al. 
2015). On the other hand, osteoclast number to bone surface ratio is unchanged as 
compared to WT mice (Garimella, Kacena et al. 2007, Meijome, Hooker et al. 2015). We 
examined whether the increase in trabecular bone volume seen in 8 month old Gata-1low 
female mice could be due to the amount of osteoclasts in femur sections. A region of 
interest was identified in the distal femur, the amount of bone surface was measured 
using Image J, and the number of osteoclasts was evaluated using the cellsense software. 
The osteoclasts were identified based on large size and positive TRAP staining (red) 
(Figure 15a,b). Within our region of interest, there was no difference in bone surface 
between the Gata-1low male and Gata-1low female femur sections (Figure 15c). There 
was also no difference in osteoclast number per bone surface area between Gata-1low 
male and Gata-1low female mice or osteoclast number per bone surface area (Figure 
15d).  Therefore, at 8 months of age, there is no difference in osteoclast number per bone 
surface area in Gata-1low male and Gata-1low female mouse femurs, although bone 
volume is greater in the female mice. 
		
92 
 
 
 
 
  
M 
GP
 
GP
 
M 
G
at
a-
1l
ow
  
M
al
e 
G
at
a-
1l
ow
  
Fe
m
al
e 
A. 
B. 
C. D. Bone Surface
Gata-1low Male (n=3) Gata-1low Female (n=3)
0
10000
20000
30000
Gata-1low Male (n=3)
Gata-1low Female (n=3)
  T
ot
al
 B
on
e 
Su
fa
ce
Gata-1low Male (n=3)Gata-1low Female (n=3)
0.000
0.001
0.002
0.003
Gata-1low Male (n=3)
Gata-1low Female (n=3)
O
st
eo
cl
as
t n
um
be
r 
no
rm
al
iz
ed
to
 B
on
e 
S
ur
fa
ce
 a
re
a
M M 
GP
 
M M GP
 
GP
 
GP
 
		
93 
Figure 15: Osteoclast number in Gata-1low male and female mouse femurs at eight 
months of age. 
Parformaldehyde fixed femur sections were decalcified, paraffin-embedded, sectioned 
and placed on slides. 32-week old Gata-1low male (A) and Gata-1low female (B) femur 
sections were stained with TRAP stain and a region of interest was identified (yellow 
box). Total Bone Surface was measured using Image J software (C). TRAP positive cells 
were counted using the Cell Sense software and normalized to bone surface area (D). 
These measurements were taken in 1 section per mouse femur. Three mice were analyzed 
per sex. M=Metaphysis and GP=Growth Plate. A student two-tailed t-test was used for 
statistical analysis of this experiment.  
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Discussion & Conclusion 
These studies were carried out in order to assess the role of sex in the progression of 
osteosclerosis in the Gata-1low mouse model of PMF. The osteosclerosis seen in the 
Gata-1low mice has been studied in male and female mice, but a comparison of the 
progression of osteosclerosis between Gata-1low male and female mice has not been 
completed.  
 We found that the progression of osteosclerosis is faster in the Gata-1low female 
mice than in the Gata-1low male mice. Kacena et al. published a study in 2004 detailing 
the progression of osteosclerosis in Gata-1low male and female mice using µCT and bone 
histomorphometry (Kacena, Shivdasani et al. 2004).  They showed that there was an 
increase in trabecular bone at the proximal and distal ends of the femur as compared to 
WT mice at 5 months and that this increase in trabecular bone increased and in many 
mice filled the marrow cavity at 9 months, but they did not note any sex differences in the 
progression of osteosclerosis (Kacena, Shivdasani et al. 2004). We have examined the 
sex differences of this phenomenon in the Gata-1low mice and found that female Gata-
1low mice exhibit increased trabecular bone within the marrow cavity at 5 and 8 months 
of age compared to Gata-1low male mice (Figures 10,11). This sex difference in 
trabecular bone within the marrow cavity was not seen in WT female vs. male mice at 8 
months or 1 year of age (Figures 10, 11).  
 We further explored possible causes of the increase in bone formation in Gata-
1low female mice as compared to Gata-1low male mice by studying Gata-1 expression 
levels in the megakaryocytes, the number of megakaryocytes in the bone marrow and 
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osteoclast activity within the bone marrow of the mice. We found similar levels of Gata-1 
mRNA expression in in vitro differentiated megakaryocytes of male and female Gata-
1low mice, suggesting that a decrease in the Gata-1 mRNA expression level was not 
causing a more severe phenotype in the Gata-1low female mice. More studies analyzing 
Gata-1 protein levels are needed to investigate whether the similarity in the mRNA 
expression level correlates with protein levels in these mice. It is likely that we may not 
find Gata-1 protein in the male or female Gata-1low megakaryocytes since the mRNA 
levels are only ~0.01% of WT levels though the correlation between mRNA and protein 
may not persist. Future studies could also include an analysis of Gata-1 expression in 
non-cultured bone marrow megakaryocytes since systemic factors not present in the 
culture dish could be impacting the expression level of Gata-1.  
Increases in TGFβ-1 producing megakaryocytes have been found to be the cause 
of the increase in osteosclerosis seen in the Gata-1low mice (Chagraoui, Komura et al. 
2002). In addition, estrogen treatment is known to increase megakaryocyte number in 
post-menopausal women and in mice (Fox and Chambers 2006). Upon examining the 
number of megakaryocytes in the bone marrow of WT and Gata-1low male and female 
mice, we noted an augmented number of megakaryocytes at all ages in Gata-1low mice, 
compared to WT, as previously published in the literature (Fox and Chambers 2006). The 
number of megakaryocytes in the bone marrow is similar between Gata-1low male and 
Gata-1low female mice at 10 weeks of age, and slightly decreased in Gata-1low female 
mice as compared to Gata-1low male mice at 20 weeks of age. This shows that 
megakaryocyte number is likely not the cause of the increase in osteosclerosis seen in the 
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Gata-1low mice as compared to Gata-1low male mice. The megakaryocytes studied in 
this experiment were limited to those that fit the criteria of being large cells with one or 
more nuclear lobules. Therefore, this analysis does not include less mature, small 
megakaryocytes with only one nuclear lobule that stain with the megakaryocyte marker 
CD41. Future studies using IHC staining of megakaryocytes with the megakaryocyte-
specific marker CD41 would allow an alternative method to analyze megakaryocyte 
number in the bone marrow of Gata-1low male and Gata-1low female mice.  
 Osteoclast-induced bone resorption has not been implicated in the osteosclerosis 
seen in the Gata-1low mice versus WT mice (Kacena, Shivdasani et al. 2004, Bock, 
Hoftmann et al. 2008). We found that osteoclast number per bone surface area is similar 
in male and female Gata-1low mice at 30 weeks of age, and, therefore, osteoclast 
abundance is not impacting the sex differences seen in osteosclerosis in the Gata-1low 
mice. Osteoblast number and OPG have been found to be increased in Gata-1low mice as 
compared to WT mice (Kacena, Shivdasani et al. 2004, Meijome, Hooker et al. 2015). 
This increase in osteoblasts could be causing an increase in the amount of bone matrix 
produced, leading to augmented trabecular bone formation. Without an increase in 
osteoclastogenesis, this would lead to more bone formation. Future studies would include 
measuring osteoblast number and OPG levels in the bone marrow of the Gata-1low male 
and female mice in order to assess if there is a correlation between OPG amount and 
osteoblast number in the Gata-1low female mice, which would lead to higher 
osteosclerosis.  
 Differences in hormone levels were not assessed in these studies and would need 
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to be analyzed in order to understand if sex hormones could be playing a role in the sex 
differences seen in osteosclerosis of the Gata-1low mice. It is known that the estrogen 
receptor can bind to and inhibit Gata-1 in the MEL megakaryocyte erythroid cell line and 
lead to apoptosis of the cells by decreased Gata-1 target gene expression (Blobel and 
Orkin 1996). Future studies would involve measuring sex hormone levels in WT male 
and female and Gata-1low male and female mice in order to determine if there is a 
correlation between estrogen/androgen ratio and progression to osteosclerosis in the 
Gata-1low mice. In addition to measuring estrogen/androgen levels in the mice, we could 
also treat the mice with sex hormones and then investigate osteosclerosis within the bone 
marrow of Gata-1low male and female mice. This would allow us to understand if 
augmented estrogen/androgens could increase or decrease the progression of 
osteosclerosis in the Gata-1low mice. In order to study osteosclerosis without the effect 
of estrogen/androgens, we could perform gonadectomy, which would remove sex 
hormones from the circulation of the experimental animals. This would allow us to 
understand if sex hormones in circulation are a cause of differences in progression of 
osteosclerosis in the Gata-1low mice. 
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CHAPTER V: CONCLUDING DISCUSSION AND FUTURE DIRECTIONS 
 Primary Myelofibrosis is characterized by both bone marrow fibrosis and 
osteosclerosis. We have attempted to understand the mechanism behind PMF by 
analyzing the impact of Egfl7 upregulation on the myelofibrotic phenotype of the Gata-
1low mice (Chapter III) and assessing the role that sex differences plays in the 
osteosclerosis seen in the Gata-1low mice (Chapter IV). In chapter III, we concluded that 
Egfl7 mRNA upregulation does not impact the myelofibrotic phenotype of the Gata-1low 
mice based on the small number of transgenic and control mice analyzed thus far. If this 
result is sustained upon analysis of a greater number of mice, one could conclude that the 
lack of a phenotype is possibly due to a deficiency of Egfl7 protein levels in the 
transgenic mice, or the inability of Egfl7 to impact collagen cross-linking through its 
ability to inhibit LOX in vivo. In chapter IV, we concluded that female Gata-1low mice 
show an increase in the progression of osteosclerosis compared to male Gata-1low mice, 
and this difference cannot be attributed to differential levels of Gata-1 mRNA in in vitro 
differentiated megakaryocytes, osteoclast number per bone surface area or 
megakaryocyte number in femur histological sections in the two experimental groups. 
Future studies on Egfl7 regulation of collagen cross-linking in vitro and protein 
expression in PF4-Egfl7/Gata-1low mice are needed to further evaluate the role of Egfl7 
on the myelofibrotic phenotype of the Gata-1low mice. Also more studies on the role of 
estrogen on osteosclerosis progression in the Gata-1low mice would help us to further 
determine the mechanism behind the increased progression of osteosclerosis in the Gata-
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1low female mice. Together, these studies would help us to further understand some of 
the mechanisms behind Primary Myelofibrosis.  
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APPENDIX I                                                                                                                        
The Role of the A2b Adenosine Receptor in Cytoskeletal Regulation 
 
Introduction 
 VSMC contraction and tension help to maintain blood pressure in blood vessels 
during blood pressure changes. VSMCs contract or dilate in response to changes in Ca2+ 
levels that result from ligand stimulation of surface receptors, which leads to changes in 
second messengers such as cyclic guanosine monophosphate (cGMP), 3’-5’ cyclic 
adenosine monophosphate (cAMP) or increases in inositol triphosphate (IP3)(Rybalkin, 
Yan et al. 2003).  Increases in IP3 lead to augmented levels of Ca2+ and contraction of 
VSMCs while increases in cGMP and cAMP lead to decreased levels of Ca2+ and 
relaxation of VSMCs. These changes in Ca2+ levels cause perturbation of the 
cytoskeleton such that VSMC contraction or relaxation results (Sturek et al. 2007). 
VSMCs have thin filaments composed of actin and associated proteins, such as 
tropomyosin, myosin light chain kinase (MLCK), caldesmon and calponin, and thick 
filaments composed of myosin. Ca2+ bound to calmodulin activates MLCK, which 
phosphorylates the regulatory light chains of myosin by adding a phosphate group to 
serine-19. The phosphorylation of myosin light chains allows cycling of myosin heads on 
actin, which causes shortening of the muscle. Myosin phosphatase is responsible for 
dephosphorylating the light chains of myosin so that the cycling and contraction stops 
(Fig. 1) (Sturek et al. 2007).  
 Stress fiber formation allows VSMCs to regulate tension in VSMCs. They are 
contractile apparatuses in smooth muscle cells that allow cells to respond to mechanical 
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force (Pellegrin and Mellor 2007). They are made up of 10 to 30 actin filaments, which 
are held together by crosslinkers. Nonmuscle myosin and tropomyosin are also involved 
in the apparatus. In contrast, microfilaments are comprised entirely of the 42 kDa protein 
actin. There are two forms of actin: G-actin (globular actin) and F-actin (filamentous 
actin). F-actin is the form that allows the cell to change shape and contract. There are 6 
types of actins; alpha and gamma smooth muscle actin, alpha skeletal, alpha cardiac 
(skeletal muscle isoforms) and beta cytoplasmic and gamma cytoplasmic actin. Alpha 
actins are expressed in muscle cells, beta actin is expressed in nonmuscle cells and 
gamma actins are expressed in non-muscle and smooth muscle cells (Chhabra and dos 
Remedios 2008). Actin binding proteins can be classified as binding monomeric or 
filamentous actin. These proteins are necessary for polymerization and assembly of F-
actin, maintenance of actin filament bundles and networks, interaction of actin with the 
membrane and the ECM as well as actomyosin based contractility. Actin crosslinking 
proteins are important for maintaining the actin filament bundle and network in order to 
allow the actin to have mechanical strength (Cruz 2008). The actin binding protein α-
actinin consists of an actin binding domain (ABD) at its N-terminus, which is linked, to a 
calmodulin like domain (CaM) at its C-terminus by α-spectrin like repeats. The ABD 
contains CH domains which allows α-actinin-1 to bind to actin while the CaM domain 
contains EF hand domains allowing α-actinin to bind Ca2+. There are four isoforms of α-
actinin, which are α-actinin-1, α-actinin-2, α-actinin-3 and α-actinin-4. The isoforms α-
actinin-2 and α-actinin-3 are present in skeletal muscle while α-actinin-1 and α-actinin-4 
are not present in skeletal muscle. Though α-actinin-2 and 3 both have the same structure 
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as α-actinin-1 and 4, they do not bind Calcium due to a mutation in the EF Hands. In 
addition to having the ability to bind actin and Ca2+, α-actinin also can bind other proteins 
at positively charged regions via its α-spectrin like repeats (Fig. 2B,C). This additional 
binding property gives α-actinin a wealth of partners to bind and thus implicates the 
molecule as a downstream molecule in signaling pathways and regulator of docking 
protein function (Otey and Carpen 2004). In collaboration with Dr. Huang Pingbo, Dr. 
Katya Ravid has found that the A2bAR binds α-actinin-1 by a yeast 2 hybrid experiments 
in yeast and coimmunoprecipitation experiments in HEK293T cells (Data not shown). 
They also found that SiRNA knockdown of A2bAR lead to an increase in α-actinin-1 
expression in HEK293T cells (Data not shown). The following studies examine the 
ability of A2bAR to regulate the expression and localization of α-actinin-1 in the 
vasculature. Co-immunoprecipitation experiments analyzing the binding of A2bAR to α-
actinin-1 in VSMCs (data not shown) have been unsuccessful thus far. 
 
Methods 
VSMC isolation 
Aorta were extracted from 8-10 week old female C57BL6/J mice at the base of the spine 
from the descending aorta up until the diaphragm and placed into cold DMEM (catalog # 
12430062, Life Technologies) supplemented with 1% penicillin/streptomycin (catalog # 
12430062, Life Technologies) in a 100 mm dish. The aortas were transferred to a new 
100 mm dish containing 12 mL of DMEM in the tissue culture hood. The adventitia was 
stripped from the aorta using forceps. The aortas were transferred to a new 100 mm dish 
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containing 12 mL DMEM and the adventitia was further removed from the aorta. The 
aortas were transferred once more to a new 100 mm dish containing 12 mL DMEM and 
the adventitia was cleaned from the aorta once again. The aorta was rinsed with 20% FBS 
(catalog# 16000-044, Lot#1680759, Gibco) in penicillin/streptomycin supplemented 
DMEM, cut into 4-6 pieces and placed into BD Primaria dishes (catalog #08-772-4F, 
Fisher) with a distance of 1 cm between individual pieces. The aorta pieces were allowed 
to desiccate slightly for 2-3 minutes and a few drops of cell culture medium was added 
carefully to each piece while being careful not to dislodge the explanted aortas. The 
explanted aortas were cultured in a tissue culture incubator at 37°C for 4 hours and 
culture medium was added gently (2 mL culture was added for 60 mm dishes and 6 mL 
was added for 100 mm dishes). The dishes were moved to the tissue culture incubator 
while being careful not to disturb the tissues so that they could remain attached to the 
dish. The explanted aortas were grown out for 3-7 days. When the cells reached 50% 
confluency, the explants were removed and the VSMCs were passaged and used for 
experiments up until passage 6. During culturing, the cells were incubated in DMEM 
supplemented with 10% FBS. 
Protein Isolation 
Mesenteric Artery and Aorta 
Vessels were isolated from 12-week old male C57BL6/J mice, snap frozen in liquid 
nitrogen and placed at -80°C for storage. Tissues were placed in Sample tubes RB 
(catalog # 990381, Qiagen) along with a stainless steel 7 mm bead (catalog #69990, 
Qiagen) and placed on dry ice. The tubes were placed at room temperature and 600 µl of 
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RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 50 mM tris pH 8) along 
with 1x proteinase inhibitors (catalog # 11697498001, Roche Diagnostics) and 1x 
phosphatase inhibitors (catalog # 4906837001, roche) was added to the tubes. The tubes 
were placed in the tissue lyser adapter (catalog #69982, Qiagen) and into the Tissue 
Lyser II (catalog # 85300, Qiagen). The Tissue Lyser II was operated at 20 Hz for 2 
minutes, the position of the adapter was changed and the Tissue Lyser II was operated 
again at 20 Hz for 2 minutes. The tubes were put on wet ice for 30 seconds in between 
runs of the tissue lyser in order to keep the lysate cold. This protein lysate was vortexed 
at 10 minutes in the 4°C cold room and placed on wet ice for 30 minutes. The protein 
lysate was centrifuged for 10 minutes at 4°C at 13,000xg. The supernatant was removed 
(without the fat) and a Bradford Assay was done to measure protein. Aliquots of the 
protein lysate were frozen at -80°C.  
Vascular Smooth Muscle Cells (VSMCs) 
Cells were washed with ice cold 1x PBS and 100 µl of RIPA supplemented with 1x 
proteinase inhibitors (catalog # 04693116001, Roche) and 1x phosphatase inhibitors 
(catalog # 04906845001, Roche) were added to VSMCs in tissue culture dishes. Cells 
were scraped with a pipette tip, transferred to a microcentrifuge tube and vortexed for 20 
seconds. Protein lysates were incubated on wet ice for 20 minutes and centrifuged for 10 
minutes at 4°C at 13,000xg. The supernatant was transferred to a new tube and protein 
concentration was measured using the Bradford Assay. Aliquots of the protein lysate 
were frozen at -80°C or used immediately for western blot analysis.  
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Western Blot Analysis 
Protein was electrophoresed on a 10% polyacrylamide gel and run at 100 mV until the 
dye front reached the end of the gel. The proteins were transferred from the gel to a 0.2 
µM Immobilon PVDF membrane (catalog # 162-0177, BioRad) at 4°C overnight in 
transfer buffer at 35 mV. The membrane was rinsed and incubated in blocking buffer (5% 
milk in 0.1% PBS-Tween-20) for 1 hour at room temperature. The membrane was 
incubated at 4°C while rocking overnight in anti-mouse α-actinin-1 (catalog #ab18061, 
abcam, 1:1000 in 0.05% PBS-T). The loading control (β-actin, α/β tubulin, GAPDH and 
α-actin) detection, the membrane was incubated for 1 hour at room temperature with 
antibodies (β-actin=clone AC-74, Sigma, 1:5,000 in 0.05% PBS-T; α/β tubulin=clone, 
cell signaling, 1:1,000 in 0.05% PBS-T; GAPDH=clone, cell signaling, 1:1,000 in 0.05% 
PBS-T; α-actin= clone, cell signaling, 1:1,000 in 0.05% PBS-T). The membrane was 
washed with 1x PBS-T three times for 5 minutes each and incubated in Horseradish 
Peroxidase conjugated secondary antibody (catalog # 70775 for rat and catalog # 70765 
for mouse, cell signaling, 1:10,000 in blocking buffer). The membrane was washed three 
more times at 5 minutes per wash in 1x PBS-T.  For visualization of protein, Millipore 
Immobilon Western Chemiluminescent Horseradish peroxidase substrate (catalog # 
WBKLS0500, Millipore) was used and the signal was developed using autoradiography 
film (catalog # E3012, Denville). 
Bradford Protein Assay 
For tissues, protein lysates were diluted 1:500 in 1x PBS and for cells, protein lysates 
were diluted 1:100 in 1x PBS.  The protein lysates (50 µl) were added to a 96-well plate 
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(catalog #9017, Fisher) in the same well as 200 µl of 1x Protein Assay Dye Reagent  
(catalog # 500-0006, BioRad) diluted in ddH2O. Standards were made using BSA diluted 
in 1xPBS at concentrations of 0 µg/µL, 0.00625 µg/µL, 0.0125 µg/µL, 0.025 µg/µL, 0.05 
µg/µL and 0.1 µg/µL. The standards (50 µl) were loaded onto the 96-well plate along 
with 200 µl of 1x Protein Assay Dye Reagent. The absorbance was read on a BioTek 
Instruments µQuant spectrophotometer at 595 nm. The protein concentrations were 
calculated for each sample after constructing a standard curve using the standards. 
mRNA Isolation  
VSMCs- Wells containing VSMCs were rinsed with ice cold 1xPBS and 350 µl of lysis 
buffer RLT plus (catalog # 1053393, Qiagen) was added per well. The cells were scraped 
off of the bottom of the dish with a pipette tip and transferred to an eppendorf tube on ice. 
The cell lysates were vortexed and transferred to a Qiashredder tube (catalog # 79656, 
Qiagen) and centrifuged at 5000xg for 3 minutes. The RNA was extracted using the 
RNeasy Plus Micro kit (catalog #74004, Qiagen) and eluted from the column with 30 µl 
of water. 
Aorta- Tissues stored at -80°C were placed in Sample tubes RB (catalog # 990381, 
Qiagen) along with a stainless steel 7 mm bead (catalog #69990, Qiagen) and placed on 
dry ice. The tubes were placed at room temperature and 600 µl of buffer RLT plus was 
added to the tubes. The tubes were placed in the tissue lyser adapter (catalog # 69982, 
Qiagen) and into the Tissue Lyser II (catalog # 85300, Qiagen). The Tissue Lyser II was 
operated at 20 Hz for 2 minutes, the position of the adapter was changed and the Tissue 
Lyser II was operated again at 20 Hz for 2 minutes. The tubes were placed on wet ice for 
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30 seconds in between runs of the tissue lyser in order to keep the lysate cold. Samples 
were centrifuged at 4°C at 13,000 x g for 10 minutes and the supernatant under the fat 
(600 µl) was added to a gDNA tube. RNA was extracted with the RNeasy Plus Mini kit 
and eluted from the RNeasy column included in the kit with 30 µl of RNAse free water. 
The RNA concentration was measured on a nanodrop and stored at -80°C freezer. 
Reverse Transcription 
The mRNA was reverse transcribed using the Applied Biosystems reverse transcription 
kit (catalog # 4368814) according to the manufacturer’s protocol. Real Time Polymerase 
Chain Reaction (RT-PCR) was done in a MicroAmp Optical 384-Well Reaction Plate 
(catalog # 4309849, Applied Biosystems). Each reaction included 1 µl of cDNA, 3 µl of 
RNase/DNase free water, 5 µl of TaqMan Gene Expression Master Mix (catalog# 
4369016, Life Technologies) and 1 µl of primers. The primer probe sets that were used 
included α-actinin-1 (Mm01304398_m1, Applied Biosystems), mA2bAR 
(Mm00439768, Life Technologies), GAPDH (catalog # 4352339E-1207039, Applied 
Biosytems) and Human 18srRNA (catalog # 4319413E-130105, Applied Biosystems). 
The cDNA to be used with 18srRNA was diluted 1:100 in RNase free water and the 
cDNA to be used with GAPDH was diluted 1:10 in RNase free water. Each reaction was 
performed in one well of a 384 well plate on a ViiA™ 7 Real Time PCR machine 
(ThermoFisher Scientific, catalog # 4453534). 
Immunofluorescence 
The following steps were taken in collaboration with Cynthia Gallant of Dr. Kathleen 
Morgan’s lab to analyze the surface to cytosol ratio of α-actinin-1 and the F-actin bundle 
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width after A2bAR agonist treatment and A2bAR KD. All immunofluorescence 
experiments were performed in the Morgan lab by Cynthia Gallant. Quantitation for 
Figure 18 was done by Cynthia Gallant while I performed the quantitation for 19.  
Protocol: VSMCs grown on etched coverslips were fixed with ice cold 4% 
paraformaldehyde for 10 minutes, quenched with 0.1 mM glycine in 1% BSA Hanks PSS 
(catalog # 14185-052, Gibco) (2 mL), and stored at 4°C until immunofluorescence 
staining. The cells were permeabilized for 10 minutes with 0.1% tritonX-100 in 1% BSA 
Hanks PSS and the cells were washed in 0.05% TritonX-100 in 1% BSA Hanks PSS 
three times for 5 minutes each. Nonspecific binding was blocked with 10% goat serum 
(catalog #S-1000, Vector Laboratories) made up in 0.05% tritonx-100 in Hanks PSS.  
The cells were washed again 3 times for 10 minutes each. The cells were incubated with 
Alexa Fluor 488 goat anti-mouse secondary antibody (catalog # A-11001, Invitrogen, 
1:1000 in Hanks PSS) for 30 minutes in the dark. Phalloidin (catalog # A12380, Life 
Technologies, 1:1000 in Hanks PSS) was incubated with the cells overnight at 4°C in the 
dark. The cells were washed with Hanks PSS 3 times for 5 minutes each. The coverslips 
were dipped into distilled water followed by Hanks PSS. Two drops of DAPI (catalog # 
H-1500, Vectashield Laboratories) was added to the coverslips and the coverslips were 
placed on a glass slide with the cell side down. The mounted slides were dried overnight 
(or at least 60 minutes) before microscope examination. Slides were stored in the 
aluminum foil at 4°C to prevent photobleaching.  
Analysis- For the surface to cytosol ratio measurement, a line was drawn through the cell 
using line scan analysis in the cell sense program. The intensity at the surfaces (surface 1 
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and surface 2) as well as three regions on the line (cytosol 1, 2 and 3) in the cytosol was 
recorded and 3 lines were analyzed per cell. The average surface over the average cytosol 
was calculated for the three lines drawn in the cell. Between 10 and 16 cells were 
analyzed per treatment. For F-actin bundle width analysis, a line was drawn through F-
actin fibers perpendicular to the direction of the bundle. The width of the F-actin bundle 
was calculated by subtracting the length of the line crossing F-actin bundles from the 
total length of the line. The fiber width was calculated on three different fibers per cell. 
The average of the bundle widths were calculated per cell in the same cells used for 
surface to cytosol ratio calculations.  
SiRNA Knockdown 
On day 1, VSMCs were plated on etched slides in a 6-well dish. On day 2, 6 µl of 
Lipofectamine RNAi Max (catalog # 13778-075, Invitrogen) was diluted in 100 µl of 
optimem (catalog # 31985-062, GIBCO by Life Technologies) and the three tubes were 
labeled A2bAR SiRNA Vial A, α-actinin-1 SiRNA Vial A, Scramble Vial A, or Water 
Vial A. SiRNA, scramble or water were added to eppendorf tubes at a volume of 6 µl to 
100 µl of optimem and labeled A2bAR SiRNA Vial B, α-actinin-1 SiRNA Vial B, 
Scramble Vial B or water Vial B. The total volume in Vial B was added to the 
corresponding Vial A and 200 µl of the mixtures were added to each well in 2 mL’s of 
media and the cells were placed back in the incubator. On day 2, 1 µl/mL of adenosine 
deaminase (catalog # 10102105001, Roche) in serum-free DMEM was added to each 
well for a total volume of 1 mL per well. After 10 minutes, 2 mM of Bay 60-6583 
(catalog # 4472, Tocris) or DMSO vehicle was added to the cells. On day 3, the cells 
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were ready for further analysis. A2bAR siRNA (catalog # J-060263-05-0005, 
Thermoscientific), non-targeting “scramble” SiRNA (catalog # D-001810-01-05, 
Thermoscientific) and ON-TARGETplus Actn1 SiRNA (catalog # J-066191-01-0005, 
Thermoscientific) were used.  
 
Results & Discussion 
The expression of α-actinin-1 in the aorta, mesenteric artery and VSMCs of WT 
and A2bAR KO mice.  
In order to investigate the ability of A2bAR to impact the expression of α-actinin-1, I 
isolated the aorta and mesenteric artery from 12-week old male WT and A2bAR KO, 
primary VSMCs of 8-10 week old WT and A2bAR KO mice as described in the methods 
section of Appendix I. There was no significant difference discovered in the mRNA 
expression of α-actinin-1 in WT and A2bAR KO aorta or the α-actinin-1 protein 
expression in WT and A2bAR KO aorta, mesenteric artery or VSMCs (Figures 15-17). 
Therefore, A2bAR expression does not impact α-actinin-1 expression in aorta, 
mesenteric artery or in vitro cultured primary VSMCs of WT and A2bAR KO mice.  
 
The impact of A2bAR on α-actinin-1 localization and F-actin bundle width 
In order to determine if A2bAR impacts the localization of α-actinin-1 and the F-actin 
bundle width, we examined VSMCs labeled with fluorescent molecules that label α-
actinin-1 and F-actin. Initial studies showed that VSMCs lacking A2bAR have less α-
actinin-1 staining on the membrane compared to WT control animals (Figure 18) and that 
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the A2bAR agonist Bay 60-6583 induces a shift of α-actinin-1 from the membrane to the 
cytosol (Figure 19). Bay was also shown to induce an increase in the F-actin bundle 
width (Figure 19). A follow-up study analyzing α-actinin-1 expression in VSMCs with 
and without treatment of Bay 60-6583 was inconclusive in visually examining if the 
knockdown of A2bAR or Bay 60-6583 treatment impacts α-actinin-1 localization and F-
actin bundle (Figure 20). A follow-up experiment with Bay 60-6583 treated and untreated 
WT and A2bAR knockdown VSMCs showed no significant difference in α-actinin-1 
localization or F-actin bundle width (Figure 21).  
		
112 
 
Figure 15: α-actinin-1 expression in the arch of the aorta of 12 week old WT and 
A2bAR KO mice.  
mRNA expression of α-actinin-1 by qPCR (A) and α-actinin-1 protein expression in the 
arch of the aorta by western blot analysis (B). Quantitation of α-actinin-1 protein 
expression in the arch of the aorta of WT and A2bAR KO mice normalized to (C) 
GAPDH and (D) β-actin. A student two-tailed t-test was used for statistical analysis of 
this experiment. n=3 biological replicates per genotype. 
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Figure 16: α-actinin-1 expression in the mesenteric artery of 12 week old WT and 
A2bAR KO mice.  
α-actinin-1 protein expression by western blot analysis (A). Quantitation of α-actinin-1 
protein expression normalized to (A) GAPDH and (B) β-actin. α-actinin-1 protein 
expression by western blot analysis in the mesenteric artery of another set of WT and 
A2bAR KO mice (C). Quantitation of α-actinin-1 protein expression normalized to α/β 
tubulin. For (A), (B) and (C) there were n=2 biological replicates per genotype. For (D) 
and (E) there were n=3 biological replicates per genotype. A student two-tailed t-test was 
used for statistical analysis of this experiment. 
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Figure 17: α-actinin-1 protein expression in pooled VSMCs from five 10-week old 
WT and A2bAR KO mouse aorta.  
(A) Western blot analysis of α-actinin-1 protein expression in WT and A2bAR KO aorta. 
(B) Quantitation of α-actinin-1 protein expression in the aorta of WT and A2bAR KO 
mice. The western blot was done with technical triplicates. A student two-tailed t-test was 
used for statistical analysis of this experiment. 
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Figure 18: α-actinin-1 localization and stress fiber formation in VSMCs isolated 
from the aorta of 10-week old female WT and A2bAR KO mice.  
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Figure 19: α-actinin-1 localization and stress fiber formation in VSMCs isolated 
from the aorta of WT mice and treated with or without the A2bAR agonist Bay.  
Illustration of the method of quantifying α-actinin-1 surface to cytosol ratio and F-actin 
bundle width analysis (A). Localization of α-actinin-1 and F-actin in VSMCs treated with 
and without Bay (B). Quantitation of α-actinin-1 membrane to cytosol ratio (C) and F-
actin bundle width (D) in VSMCs treated with and without Bay. A student two-tailed t-
test was used for statistical analysis of this experiment.  
	  
		
119 
 
Figure 20: α-actinin-1 localization and stress fiber formation in VSMCs isolated 
from the aorta of WT and A2bAR KO mice and treated with or without the A2bAR 
agonist Bay. 
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Figure 21: The impact of A2bAR expression and Bay treatment on α-actinin-1 
localization and stress fiber formation. 
α-actinin-1 localization and stress fiber formation in VSMCs isolated from the aorta of 
WT mice and treated with or without the A2bAR agonist Bay and A2bAR SiRNA (A). 
A2bAR expression in VSMCs treated with and without Bay and A2bAR SiRNA (B). 
Quantitation of F-actin bundle width in VSMCs treated with and without Bay and 
A2bAR SiRNA (C). Quantitation of α-actinin-1 membrane to cytosol ratio in VSMCs 
treated with and without Bay and A2bAR SiRNA. A two-way ANOVA with the 
bonferonni post-hoc test was used for statistical analysis of this experiment. * and ** 
denotes a significance of p<0.05 and p<0.01 in experimental samples, respectively 
compared to the WT samples of the same treatment.   
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APPENDIX II                                                                                                                  
The Role of the A2b Adenosine Receptor in Blood Pressure Regulation 
Introduction 
 Cardiovascular disease is a leading cause of death in the United States . One of 
the greatest risk factors for cardiovascular disease in the US is hypertension given that 
one in three adults in the US has high blood pressure (BP) or is on pressure lowering 
medication . There are two subtypes of hypertension: primary (essential) and secondary 
hypertension.  Primary hypertension is high blood pressure due to an environmental or 
genetic cause, while secondary hypertension is due to a well-characterized underlying 
cause such as hyperaldosteronism or a pheochromocytoma. The metabolite adenosine has 
long ago been described as a vasodilator (Green 1952). Despite its vasodilatory effects, 
adenosine has never been used as a BP lowering drug due to its short half-life and ability 
to stimulate four different receptors. Each of its receptors has a different expression 
pattern in tissues as well as different down stream targets so that upon stimulation, cells 
may respond differently to adenosine depending on the receptor that was activated 
(Gessi, Merighi et al. 2011). 
 The four Adenosine Receptors (ARs) that adenosine activates are A1AR, A2aAR, 
A2bAR and A3AR which are G-Protein Coupled Receptors (GPCRs). When A1AR and 
A3AR are activated, Gi is stimulated which leads to decreases in 3’-5’ cyclic adenosine 
monophosphate (cAMP) levels and signaling. When A2aAR and A2bAR are activated, 
Gs is stimulated and an increase in cAMP signaling occurs (Gessi, Merighi et al. 2011). 
The increases in Ca2+ upon stimulation of VSMCs with adenosine is responsible for 
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vasodilation which may be due to its actions on ARs (Kai, Kanaide et al. 1987). In the 
case of the A2bAR, Gq is also activated, resulting in the formation of inositol 
triphosphate (IP3), which can promote the release of calcium into the cytoplasm (Wilson 
and Mustafa 2009). An earlier study showed that knockout of the A2aAR leads to an 
increase in pulmonary arterial pressure (Xu, Gong et al. 2011). Our lab has engineered an 
A2bAR knockout (KO) mouse and shown that this receptor is important in controlling 
inflammation, platelet aggregation, intimal thickness after vessel occlusion, and 
atherosclerosis, ((Yang, Koupenova et al. 2008),(Koupenova, Johnston-Cox et al. 
2012),(Yang, Chen et al. 2010),(Yang, Zhang et al. 2006)) which have all been 
implicated in the development of  hypertension. Given these findings and our knowledge 
of adenosine being a vasodilatory molecule, we hypothesized that the A2bAR KO mice 
would have increased BP and aortic contractility compared to control WT mice.  
 
Methods:  
Radiotelemetry  
The following steps were taken in collaboration with Dr. Francesca Seta to measure 
blood pressure in WT and A2bAR KO mice using radiotelemetry. Implantation of 
telemetry blood pressure transducers were performed following standard procedure 
recommended by the transducer's manufacturer Data Sciences International (DSI). Blood 
pressure was monitored in conscious mice in the ascending aorta via cannulation of the 
left carotid artery with a PA-C10 transmitter device DSI. Mice were kept on a heating 
pad (37°C) during the surgical procedure to maintain body temperature and avoid 
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dehydration. All surgical procedures were conducted in aseptic conditions. Anesthesia 
was induced by 5% isofluorane inhalation and maintained by 1.5- 2% isofluorane 
inhalation. Pre-emptive analgesia was given (buprenorphen 0.03 mg/ml; 10µl/g body 
weight) as recommended by IACUC guidelines. Hair was removed with a depilatory 
agent (NAIR) to avoid contamination with hair during surgical manipulations, and a 2 cm 
incision, approximately from the lower mandible to the sternum, was performed 
longitudinally slightly to the left of the ventral midline. Surgical iodine solution was used 
to clean the surgical area from incision site to the edge of the shaved area, followed by 
70% ethanol solution and rest of the body was covered with sterile cloth. The left carotid 
artery was isolated by gently dissecting the surrounding connective tissue. A 6-0 silk 
suture was used to permanently occlude the carotid artery at the bifurcation of the interior 
and exterior arteries. Blood flow was temporarily occluded to facilitate catheter insertion 
approximately 0.5 cm posterior to the bifurcation. A sterile 25-gauge needle bended at 
90° was used to puncture the vessel and guide the catheter into the vessel. After proper 
catheter insertion, both anterior and posterior ligations was secured with knots to assure 
that the catheter was anchored in place. The transmitter portion of the device was 
positioned subcutaneously along the right flank between the front and the hind limb by 
performing a subcutaneous pocket with blunt scissors. The incision was closed with 
absorbable 6-0 suture. After full recovery from surgery, aided by the use of a heated 
chamber, mice were returned to LASC and monitored for the following 72 hrs. Analgesia 
was administered every 8 hours during the first 48 hours after surgery and as needed 
afterwards. Baseline measurements were taken for 8 days. Next, the A2bAR antagonist 
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PSB1115 (catalog # 2009, Tocris) was given to the mice via IP injection at a 
concentration of 2 mg/kg. After a 3-day washout of PSB1115, the A2bAR agonist Bay 
60-6583 was given to the mice via IP injection at a concentration of (0.01 mg/kg) for 
three days after baseline measurements were taken.  
Direct Pulse Wave Velocity (PWV) and Blood Pressure (BP) Measurements 
The following steps were taken in collaboration with Dr. Francesca Seta to perform 
invasive blood pressure and PWV measurements in WT and A2bAR KO mice. The mouse 
was placed in the recumbent position on a heating pad to maintain body temperature. 
Anesthesia was induced by 5% isofluorane inhalation and maintained by 1.5- 2% 
isofluorane inhalation. Hair from the dorsal region was removed using hair removal 
cream. A 1.5 cm incision was made in the neck area from approximately the lower 
mandible to the sternum. The right jugular vein was carefully dissected from surrounding 
tissue and a PE-10 cannula was inserted for later infusion of fluids or phenylephrine. The 
left carotid artery was gently dissected free of connective tissue and carefully separated 
from the vagus nerve. Three 6.0 silk braided sutures were placed around the carotid 
artery: the distal suture was used to permanently occlude the vessel at the level of carotid 
bifurcation; the proximal suture was gently pulled upwards with hemostatic clamps to 
temporarily occlude the blood flow during catheter insertion and the third suture was 
used to secure the pressure catheter after insertion. By using a 25G needle bended at 90°, 
the carotid artery was punctured and a pressure transducer (Millar, Micko-tip, 1F) was 
gently advanced in the carotid artery until the aortic arch. Next, 20 ms of stable blood 
pressure recordings were obtained as soon as the catheter is inserted into the carotid 
		
126 
artery. The catheter was advanced into the aorta for PWV measurements. The sutures 
were tied around the artery in order to keep the catheter in place during the recordings. A 
few drops of 2% lidocaine were applied topically on the carotid artery to reduce 
vasospasm during vessel catheterization. Once the pressure catheter was inserted into the 
aorta, the pressure waveforms were recorded for 5 minutes continuously at baseline and 
after injections of phenylephrine (0.01-10 µg/kg BW). At the end of the recordings, the 
mouse was euthanized by isofluorane overdose (5%) and death was confirmed by 
incision of the chest cavity in accordance to IACUC and AVWA guidelines on 
Euthanasia, June 2007. 
Vessel Contractility: The following steps were taken in collaboration with Qian Qian Lin 
of Dr. Kathleen Morgan’s lab to measure aortic contractility in WT and A2bAR KO 
mouse aortas. Vessels were isolated and vessel contractility was measured according to 
the protocol by Marganski et al.(Marganski, Gangopadhyay et al. 2005) This method 
consisted of immersing the vessels in a water bath containing physiological saline and 
then attaching each one to a force transducer. The vessels were stretched to ~1.3 times 
their resting length, equilibrated and then stimulated for 10 minutes with a depolarizing 
solution containing 51 mmol/L KCl or 0.01 µM Phenylephrine and measurements of 
contractility were taken. 
	  
		
127 
Results:  
Blood pressure measurement in WT and A2bAR KO mice. 
In order to examine the ability of the A2bAR to impact blood pressure regulation, we 
used a pressure transducer to measure the mean arterial pressure in the carotid artery of 7-
month-old male WT and A2bAR KO anesthetized mice. There was a significant decrease 
in the blood pressure of A2bAR KO mice detected as compared to WT mice using this 
method (Figure 22). In contrast, a significant decrease in mean arterial pressure was not 
seen in the male A2bAR KO mice as compared to male WT mice at 4-7 months mice 
using radiotelemetry (Figure 23). Using radiotelemetry, a significant increase in pulse 
pressure was identified in A2bAR KO mice as compared to WT mice at baseline (Figure 
23). The injection of the A2bAR inhibitor PSB1115 and the A2bAR agonist Bay 60-6583 
did not impact blood pressure by an A2bAR dependent mechanism in WT and A2bAR 
KO mice using radiotelemetry to measure blood pressure. There was no difference in 
body weights of WT and A2bAR KO mice in these blood pressure experiments (Figure 
22, 23D). 
Measurement of contractility in WT and A2baR KO mice 
In order to identify the impact that A2bAR has on the contractility of blood vessels, we 
measured the ability of aortas from WT and A2bAR KO mice between the ages of 3 and 
13 months to contract ex vivo upon treatment with phenylephrine and KCl. There was no 
significant difference detected in the contractility of the upper or lower thoracic aortas 
with treatment of KCl or phenylephrine (Figure 24, 25). A significant decrease in the 
cross-sectional area was detected in A2bAR KO mice as compared to WT mice (Figure 
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26). Also, the body weights of the A2bAR KO mice were significantly increased in the 
contractility measurements, which is contrary to previous experiments (Figure 22, 23F, 
25D).  	  
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Figure 22: Body Weight and Direct blood pressure measurement of WT and A2bAR 
KO mice at 7 months old.  
A student two-tailed t-test was used for statistical analysis of this experiment. * denotes a 
significance of p<0.05 in experimental samples, respectively. n=5 animals per genotype. 
 
Body Weight of WT and A2bAR KO Mice
WT A2bAR KO
0
10
20
30
40
50
B
od
y 
W
ei
gh
t (
g)
3"
Blood%Pressure%measurement%in%7%month%old%anesthe2zed%male%C57B/
6J%WT%and%A2bAR%KO%mice%
		
130 
 
 
Figure 23: Blood pressure measurements in WT and A2bAR KO mice measured by 
Radiotelemetry.  
Heart rate (A), Diastolic Arterial Pressure (B), Mean Arterial Pressure (C), Systolic 
Arterial Pressure (D) and Body Weight (E) measurements in 7-month old male WT and 
A2bAR KO mice. A two-way ANOVA with the bonferonni post-hoc test was used for 
statistical analysis of this experiment. * and *** denotes a significance of p<0.05 and 
p<0.001 in experimental samples, respectively. n=5 animals per genotype. 
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Figure 24: Stress measurements in WT and A2bAR KO mouse aortas treated with 
0.01 µM Phenylephrine.  
Stress of Upper (A), Lower (B) and Combined upper and lower thoracic aortas treated 
with 0.01 µM Phenylephrine. A student two-tailed t-test was used for statistical analysis 
of this experiment. n=8 animals per genotype. Data are representative of mice between 
the ages of three and thirteen months.  
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Figure 25: Stress measurements in WT and A2bAR KO mouse aortas treated with 
51 mM KCl.  
Stress of Upper (A), Lower (B) and Combined upper and lower thoracic aortas treated 
with 51 mM KCl. A student two-tailed t-test was used for statistical analysis of this 
experiment. n=8 animals per genotype. Data are representative of mice between the ages 
of three and thirteen months. 
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Figure 26: Cross-sectional area of WT and A2bAR KO mouse aortas.  
Cross-sectional area of Upper (A), Lower (B) and Combined upper and lower thoracic 
aortas treated with KCl. Body Weight of WT and A2bAR KO mice (D). A student two-
tailed t-test was used for statistical analysis of this experiment. n=9 animals per genotype. 
Data are representative of mice between the ages of three and thirteen months.  
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